http://www.clipsyndicate.com/rss/feed/367 http://player.clipsyndicate.com/view/367/846159 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/846159?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2009/2/23/58/351/d527fc67-2729-4fb4-835c-b9cc76dbfba2_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Interview with Chairman/CEO Henri Termeer (Bloomberg News)</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/846159?cpt=8&wpid=98 Mon, 23 Feb 2009 19:12:48 +0000 Spotlight - Genzyme Interview with Chairman/CEO Henri Termeer (Bloomberg News) http://www.clipsyndicate.com/video/playlist/367/846159?cpt=8&wpid=98 Bloomberg shares of genzyme are losing pressure today. the company reported a 10% increase in fourth quarter profits. the company ceo is in our spotlight today. he joins us from our boston bureau. bloomberg terminal today showing there are 19 buys, 2 holds and no celebrating on your stock. in recent filing shows many analysts are reducing positions. why do think that is happening? >> i do not know if that has been happening. the stock has been strong this year. it is up 5%. the dow jones has been down, as you know. we're in a good position. we projected earnings up from about four dollars last year. we are doing quite well despite the very difficult economy. >> you recently reported fourth quarter growth of 9.8%. what was the main driver of that? >> we have products in the mature phase. most products that we have are very much in the market development phase. this is happening across the board and across the world. >> the economic climate -- how is that factoring in to what's going on in company? >> we're like everybody else. we are impacted by it. we are concerned about. we deal with many national governments. of course, many of our customers to feel the squeeze. the kind of products we have are very important from a clinical point of view, from a health- care plan of you. it is not the first place where people go to find savings. we find that the products continue to the very good demand. >> speaking of products, let's talk about -- how much as the current 2009 forecasts depend on the sales of this drug? given way said across the world, not just the u.s., how will that affect sales? >> myozyme is a new product. it has not been approved in the u.s. in that sense, we're very much in the early phase. we think the product has a potential of being a billion dollar plus product. last year we did $300 million. we still have a long-term of growth ahead of us. >> this drive is for the treatment of the rare genetic disorder. -- this drug is for a rare genetic disorder. people are losing their jobs. if they're losing their jobs, they're going to lose their health care in many instances. that is seriously going to affect their ability to pay for drugs like this. what is your company doing on that front? >> we have a policy on a global basis. we have a one price policy, or for free. we do not put the patient in the middle. the kind of therapies that we have are very important clinically. we're the only supplier of many of these therapies. we make sure that patients are taking care of. we find enormous support for this across the board, in countries throughout europe, throughout asia, and throughout latin america. this policy to make sure that patients to get access, where ever these patients are, does find support. we do get very good revenues as well. >> any indications from when you may hear back from the fda? >> we would expect that at the end of this month. they're working very hard. we expect that we will hear something around that time. >> what is the company's long- term growth strategy? do you need to make medicines for more common diseases like diabetes as opposed to the more rare disease drugs? >> we have a number of programs in the works. the most important long-term program is a treatment for multiple sclerosis, which has failed much larger footprint. we're in two phases. a lot of these trials will finish enrollment very shortly, within the first half of this year. then we would expect that by 2012, we will have this product approved. of course, we have to wait for the clinical results. we have had very good results from this program in phase two. we also are in a collaboration with another company. we have a number of different things. >> we will have to leave it there. thank you very much for your time. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=846159&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=846159&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NASDAQ:GENZ Law & Legal Issues,Health,Shopping & Commerce,Business,Economy,Pharma,Bio-tech,International http://player.clipsyndicate.com/view/367/819262 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/819262?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2009/1/26/58/351/a4bb48fb-fd79-4efd-b4a1-56d8969a6280_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Live! From Pfizer's HQ in New York, NY: Pfizer CEO Jeffrey Kindler and Wyeth CEO Bernard Poussot Answer Questions After Sealing $68 Billion Acquisition Deal (FULL CLIP - 15:52)</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/819262?cpt=8&wpid=98 Mon, 26 Jan 2009 15:13:40 +0000 Exclusive: Pfizer & Wyeth News Conference Live! From Pfizer's HQ in New York, NY: Pfizer CEO Jeffrey Kindler and Wyeth CEO Bernard Poussot Answer Questions After Sealing $68 Billion Acquisition Deal (FULL CLIP - 15:52) http://www.clipsyndicate.com/video/playlist/367/819262?cpt=8&wpid=98 Bloomberg will you moderate this for us? go ahead, ray. >> there is a call number where folks are listening. we have about a little over 40 minutes to ask questions. there are hand-held microphones. jeff, who would like to ask the first question? can we boost the audio? it's done. ok, yes. > just wanted to ask you, during the conference call, i just want to clarify that end of 2012 adjusted earnings will be similar to 2008? >> yes. >> i guess the question for investors is, since it is flat earnings, will this require a certain amount of patients by investors to be satisfied with the flat earnings until 2012 or is the current share price. of pfizer low enough where it would warrant? >> the important thing is we have by virtue of this transaction, we will be able to put to sea -- to put together a set of businesses and people that will be able to produce consistent and stable earnings over the long term and create a platform to improve shareholder value, beginning now through 2012 and beyond. i think investors have rightfully been concerned about the clarity about what happens when lipitor goes off patent. i have no doubt it has weighed on the stock price. pates -- today's announcement has definitely answer the question of what has been a shareholders' minds. >> growth, will it require a lot of patients by investors or would you expect them to be satisfied with flat earnings through 2012? should they put their money elsewhere and a sluggish earnings growth? >> i think we are going to see very consistent and steady earnings that will position the company for long-term profitable growth, beginning in 2012 but even between now and then, we will do everything we can to maximize revenues and improved performance. franc -- mike chief financial officer wants to add something. >> the other thing to rember with this question is, street expectations for the company to bank -- > , over where they can see you. > remember street expectations for the company are about $2 up to $2.05 for 2012. when we make a statement that 2012 earnings will be comparable to 2008 earnings, the fact of the matter is from a street perspective, one of the factors impacting the stock price, that is a significant improvement than what currently is estimated in the industry. >> yes. [inaudible] >> i will make comments and perhaps bernard would like to add to it. we established a set of strategies for our company and have been very clear about what they are. we want to optimize our in line and pipeline portfolio to address the biggest areas of unmet medical needs, greatest need for patience, and there are specific disease areas where we want to enhance our abilities. we want to grow in emerging markets and established products. complementary business. and we want to be leader of its therapeutic vaccine. no other company beyond wyeth that is a perfect fit for the strategies. in one single transaction the combination possesses every single one of those strategies. and the businesses are very complementary. bernard and his team have done a superb job in leading a great company with terrific people and advances in science and it fits nicely with our company and i just can't imagine a great combination. would you like to elaborate? >> thank you very much. it was very obvious why we started to talk and the subsequent months, the fed was really remarkable. ypf is a company that has built relentlessly over the last 20 years -- wyeth, build the most diversified of today. we started in the early 1990's with bets at the time that looked very adventuress. we were able to bring products -- combination with the blood products. we realized early that if he wanted to be a strong scientific company in bringing products, vaccines that make you the rest of people, you have to increase those early. in doing this -- bringing talents that we did not have necessarily. what we achieved today the leading biotech products sold in the world is enbrel, which has changed completely the lives of rheumatoid of rightist patients. in my 30 years in this industry, the first product where people stop you to tell you their stories about the effect of such a product. that is the kind of excitement we have had a on this side of the business. and then prevention has been for us a very important to addiction. already are wet -- eradicate smallpox and polio. vaccine to children worldwide. it has become the largest selling vaccine in the world, period. we have more and of pipe for meningitis vaccine that exist today. prevention really a way to tackle health care costs. no more efficient way to prevent diseases. with vaccines, meaning you can cover a large population of children. medically but also socially. as a result, the we believe we became a very good match for pfizer. not to mention the strong biological arms and animal health. we were the first to bring the age 5 and 3 vaccine against avian flu couple fluh5n3 -- h5n3 vaccine for avian flu. population's getting ever about risks for animals and we eventually consumed. so we have been employing the best technologies to improve what matters to people. from that standpoint it became obvious and our discussion. we believe that this combination will just accelerate. giving new otc back, which i know you appreciate, too. >> we will take a call from the philadelphia inquirer who asked -- what is going to be the impact on r&amp;d globally in the combined company. sanford c. bernstein saying you may have to cut 70% of the combined group. >> research in development is the core of of any bicycle company. where innovation comes from, where opportunities are addressing the health but bernard was talking about come from. we respect and value it. our intent in insuring the r&amp;d continues to be robust and successful. in that regard we will be very thoughtful in integrating the two companies with a very clear understanding that we want to protect admission and ensure the great scientists and both companies are doing their job in bringing the medicine forward. we are confident we can do that. we understand the priority and what will help us is integrating these companies very quickly unfulfilling and being very careful to protect the core assets that make both of the company's successful. >> we believe that wyeth that our scientists are our strategic planners. i think it illustrates the point. you want to make your scientists able to use the best analogy is to go after the most difficult diseases that is why the science is going mass of late after alzheimer's. projects including small molecule, biotechnology and even vaccines to try to get at alzheimer's, a product that will halt the progression of the disease or even reverse it. a big goal. a lot of talent and resources. the we believe that it is the kind of thing but this company would even allow further. these resources for us to win against diseases, a plague of modern times. >> business week. the big criticism is this deal does not address a lot of the long-term pressures facing the industry, such as pricing pressures, shallow pipelines and marketing restrictions. how do you counter it? >> we believe this deal is transformational and positions the company to be in the best possible position for future success in almost any operate -- economic or operating environment. the key to success in the future of the by, -- by zero pharmaceutical and mystery begins and innovation. and virtue of the combined assets, the scientists and resources, we will be very successful in the core mission of advancing health, which is a very expensive and risky and costly proposition. we will be stronger even to do that. but as of a threshold for the companies, which is critically important and the environment. in addition, while diversifying our business so significantly and addressing the unmapped -- >> you are watching the news conference of the deal of pfizer to buy y s four $68 billion in cash. you see the pfizer ceo answering questions we are also looking at a picture of the presidential podium there. president obama is expected to speak in just a few moments. he will make remarks about jobs, energy independence and climate change. he will bring you back and switched to that as soon as we see the president approaching. let's listen in still to the fis a news conference. >> contrary to a lot of use, i think there is an opportunity to reform health care a special in the united states and with that are going to be very good for patients and societies and in which we can play a constructive role. bernard was talking but the importance of prevention. if we as a country can shift our investments and put greater focus on prevention of disease than curing disease we could have both a more efficient and productive health care system and will also save a lot of lives, which is also the most important. today this country spends 3 cents on every dollar on prevention. that is wrong. we as a company and combined with wyeth will be in a great position to be in support of government policies to prevention of illness and treat illness effectively and efficiency and that will be to the benefit of society is as a whole as well as to the shareholders. >> the cost of alzheimer's is not the cost of the drugs that exist today but it is the cost of not having drugs to eradicate or stop the disease. so that is also a way to tackle the unbelievable staggering costs coming at us. >> jeff, first question is for you. researchers employees pursuing the past acquisitions really hurt morale and slowed down productivity and put in the layers of management and real is disrupted things. now they say they feel like a lot of improvements have been made and things are getting on track. i guess, what do you say to them to insure them that this will not happen again? the an abusive relationship where they are put in the same position before. but art, my same question. if you can give me insights into your decision making and how he came to the decision that this was the right direction? >> i think first of all we obviously learned a lot from the prior acquisitions. there is no question and i have said publicly that a lot of the turmoil that those acquisitions have created definitely hurt morale, no question about it. but what we have done in the past two years we have strengthened the company and created an organization and culture that i think prepares us to do the transaction from the position of strength and in a way that reduces or minimizes those disruptions of the past. an example -- today we have a research organization with far fewer layers and far less bureaucracy and much more streamlined and most importantly, one of which scientists make decisions need to make to announce science. we have put our therapeutic areas of focus and the hands of world-class scientific officers running relatively small organizations focus on particular disease areas and we have no intention of changing that model. by virtue of having that approach and having organized ourselves, clear goals and accountability, as well as the ability of the scientist to do what they do best, we are in a much better position to bring on board the traffic assets and scientists and people and programs that wyeth has been developing all these years. it is very important to understand that this is very different from prior large pharmaceutical mergers. this is not about a single product. it is not about cost cutting -- although there clearly will be productivity improvement -- but it is about creating a broad diversified portfolio, ones in which the people who are great at science can do what they do best and those great at providing access to customers can do what they do best. it is a perfect fit of bring these two assets together and organizing the company in a way that allows us to do the integration with a minimum of disruption there and we are determined to continue to achieve a very aggressive r&amp;d goals we set out. and we have made tremendous progress and a short period of time. we will start clinical backwards. if anything, we will do better to accelerate the progress. and a short period of time the r&amp;d leadership in the company has advanced the pipeline in meaningful ways. we understand how and why that has happened and what we need to preserve that and we are determined to do it. >> you have been watching and listening to the pfizer press conference, the news conference to buy oil for $68 billion. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=819262&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=819262&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:PFE, NYSE:WYE Law & Legal Issues,Health,Shopping & Commerce,Business,Economy,Pharma,Bio-tech,Government & Politics,Editors Pick http://player.clipsyndicate.com/view/367/812868 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/812868?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2009/1/20/58/351/0245460a-d989-4a32-b735-909dc9d6998c_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">CEO of Henry Schein</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/812868?cpt=8&wpid=98 Tue, 20 Jan 2009 03:02:05 +0000 Night Talk: An interview With Stanley Bergman CEO of Henry Schein http://www.clipsyndicate.com/video/playlist/367/812868?cpt=8&wpid=98 Bloomberg raft of trading. >> medicine and music, we will talk about health care with stanley bergman. then we will talk to a jazz singer kurt elling. we welcome you to "nightalk" and we proudly welcome stanley bergman to the program, ceo of henry schein, in nasdaq company. it is a pleasure to have you here right now. also it is good to be able to address a lot of these very important and interesting issues. there could be a new change with the coming of the new administration. what you anticipate from a business standpoint and what you have been able to cheer? do you think that the business will be impacted substantially. -- what have you been able to hear? >> we think that access to care, the ability for patients to find a local physician or a hospital has improved. on the other hand, the reinvestment will go down. that will require the health care practitioner to think more about the business aspects of the practice so that the practice can be run profitably so that they can focus to access to care and health-care issues. >> you are the largest distributor of health-care products primarily to practitioners and hospitals. >> we are the largest distributor of health-care products and related services including software and financial services to office-based practioners which are private practicers. this is primarily in the developed world. >> you are talking about the reimbursement which physicians said that they are unhappy about. they have to get reimbursement from insurance companies and medicare and in many cases they have installed. does that put pressure on you? > well, it gives us the opportunity to talk to the practioner about methods of running a small enterprise because actually if you think about it, the practitioner is running a small to medium-sized enterprise. in that enterprise, they have to perform all of the normal business activities that you will find in any small business and of course they will undertake clinical care. we have about 3000 field service consultants. these are our representatives which are involved in consulting. they work with a practitioner on increasing the productivity and profitability and marketing aspects of the practice. as demand for healthcare services increases and the reimbursement goes down, we have a lot that we can offer the practioner. >> the pressure that might be there in terms of their need to purchase flu vaccines, which are involved, that can be offset or addressed by helping to realize areas of contact profit potential. -- of untapped profit potential. >> we can help in the procedures was running the practice. for example, something that will be very important for years to come as a result of the policies of what we expect from the obama administration. this will be in the area of electronic medical records. this will be very good for running the practice. of course, this will reduce mistakes and the productivity of the hospital. it is quite expensive to install an electronic medical software system. we think that the new administration will encourage this and provide the resources and the incentives to get this done. we will have a terrific solution for the practioner. we do have a terrific solution for the practitioner. >> we have heard about tax credits or some grants. >> well, the way it works, for example, with medicare and medicaid reimbursement, is that for practitioners that submit their claims electronically, they get their payments paid faster. they get an incentive from a cash flow point of you to do this. we expect similar kinds of legislation to do this. - they get an incentive from cash flow to do this. ultimately we want to have the optimization of health care systems. >> there is evidence that suggest that the mistakes go down substantially with electronic records. >> yes, that is true. not only in office but also the connectivity and the laboratories. all of this will be significantly improved. >> let's pick it up there and talk about some of the vaccine issues and the potentials there of that with stanley bergman in a moment. >> stanley bergman is our guest, he is the ceo of henry schein. we have seen what the stock markets have done over the past year. the research i have is last february, about a year ago, stock was at a 52-week high. it was about $62 a share. now it is about $56. what is that all about? we have seen many companies see the chart to go this way over the past year and no one is immune to that. describe what has been going on in stocks. > well, obviously there is an overreaction in general. i think that the stock market, i am not sure if the price of the stock is really reflected in what we're doing now. we have been doing well since we have been public. the markets are growing. right now, it is at a slower rate. the consumers, the physicians, and even the companion animal that marion's. the profits are there. -- and even the companion animal vets. >> is there an understanding that this is the way things are right now? >> you have to run the company for what is right for the customer, for our suppliers, our investors. that is what we have been doing. we are very enthusiastic about the company and the markets that we are in in the developed world. the markets are very robust from the competive landscape. it is highly fractionalized. we are dealing with enormous challenges that we can help our customers with. the enthusiasm in the company is there. we have not cut back on our human capital. we have had a reduction of a number of employes by 2.5% because we thought that was the right thing to do but overall this is quite modest compared to what other companies are doing. overall, the morale is for good. i think enthusiasm is also there. the markets are something that we cannot control nor should we be focused on. >> at this point, dealers anticipate any more lost? >> -- do you anticipate any more loss? >> i don't think so. i think that we will be okay. the demand for our services is in a time of economic downturn. i believe the public understands that preventative care is important. if you take care of your teas, your shots, you will be living a better quality of life. -- if you take care of your teeth. many people are visiting our customers. there is only a little bit of a downturn but generally the momentum is pretty good amongst our customers. >> we are talking about vaccinations and the flu vaccine is one that we use a lot during the flu season. every year, there's always talk about it. will there be enough flu vaccine? will it be the right kind of flu vaccine this year? you are about as big as they come when it comes to this kind of thing. > we believe that we're largest distributor of flu vaccine. this is a concern every year. there has been an issue one time or another with a real shortage and this is because one of our suppliers in the u.k. had an issue. today, the manufacturers of flu vaccines are all of the large farm pharmaceutical companies. there is good coordination between the manufacturers and the government. i think that we can expect drug availability, flu vaccines to be covered this year. i think that the manufacturers are optimistic. >> at this point, and enough of the insurance companies have finally decided to reimburse the practioners for the flu vaccine. does this impact your sales? >> yes, the reimbursement is very helpful. generally, the elderly population gets reimbursed under medicare. we expect a generally a reimbursement to go up as the federal government sponsors greater access to health care. overall, the flu shots, $25 is a very good investment. quest considering what you go through without it. -- >> considering what you go through without it. >> 1000 americans die every year from the flu. >> you know we think about it as something simple, you feel horrible, but you can still die from it. talk to me about acquisitions. >> the markets that we are in that account for about $25.5 billion worth of business. that is dentists, physicians, and companion animal vets. we have a 23% market share. the rest of that is in the hands of relatively undercapitalized competitors. those competitors present a huge opportunity for us to further consolidate. we are purchasing companies in the developed world, europe, australia and new zealand, canada, to advance our business. >> last week, you have three european companies. >> last week, we acquired the leading supplier of dental equipment in italy. we are already the largest provider of consumable products to densest in italy. with these two companies we will increase to our service to italian dentists. -- we are the largest provider of consumer products to dentists in italy. we are also acquiring a medical supply company in germany and this makes us the largest player of equipment products for physicians. we also acquired an animal products company in the czech republic which makes us the largest in that arena. this provides us with a footprint into eastern europe. >> let's take a break and then talk about where things are going and how your company positions their selitself. stanley bergman, the ceo of henry schein is our guest. >> stanley bergman is our guest, he is the ceo of henry schein which is one of the largest health-care distribution companies. 20 companies right now, do you anticipate going into more? > yes, we anticipate covering the entire geography developed world. this includes parts of eastern europe, north america, australia, new zealand. >> that is a major expansion. >> yes. we will continue growth in a balanced and similar way to the way in which we have historically grown the company. when we went public in 1995, the markets were in account for about $10 billion worth of business. now the market is to end a half times the size but we have increased our market share by four times. >> are you contemplating any acquisitions and will they be announced in any short order? >> we don't know about an acquisition until it is closed. these things only happen when they happen. we have a pipeline which we have always had traditionally and we will expect to make acquisitions in that geographic footprint in the medical, dental and area. >> do you see this growing at a faster rate? >> no, it is just that we look at companies that can help us provide value for our customers and our company. > the health care policy in this country, if it changes, how much of it will be medical health care? i presume that health care for animals would not be affected. would to dental care be changed? >> we think that a significant change will be in the medical arena and there will be a continued movement on health care delivered from a hospital setting into the office setting. we believe this is the area we should focus on. >> with some much discussion and development towards large companies putting in medical offices of swords, north practioners and seeing patients. -- with so much discussion and development stores large companies putting in medical offices of sorts, nurse practioners seeing people, does this affect you? >> no, we can screen patients and direct them to the practioner. this does result in better compliance. we don't see this as a major movements. we see a community center is opening up. we see the federal government opening up community centers in rural areas and underserved urban areas. we want to provide more in the area of preventive area. >> as we turn the calendar page into this year, there was a voluntary agreement between some of your companies to engage in educational encounters with physicians in their offices. too great extent, it means that there will be no more free lunches. does this affect your company? >> this does not affect our company but what you are describing is bringing moderation. we will not stop providing educational programs but it will be much more moderate. we have seen this in europe for several years. i don't think it will have any impact on our business. all of our promotions are ethical and appropriate. >> do you think that some of the companies within the field have been unethical or inappropriate? >> there has been some [unintelligible] but i think that there's moderation and it is controlled by the manufacturers themselves. this is not a government issue. this is self regulation. >> will physicians still have the kind of information at hand or the exposure to new products that they have had before? in the process of getting rid of some of these freebies, will a source of information be deprived in a way that could perhaps hurt patients? >> there is a challenge. some of the big pharmaceutical companies are laying off their cells forces. -- sales forces. we provide a marketing service as well and particularly for the smaller practice. this gives us an opportunity to give greater value for the manufacturers. >> we hear so many people talking about this. my wife is a physician in a small practice setting. there are those who say that to those kind of practitioners, many of them say this, that they see this as a dying field, that they are being pressured out by large institutional medical groups or organizations that would like to see consolidation of the industry. do you see these groups as surviving? >> yes, the backbone of health care in the office space setting of this country is very much dependent upon the small practice. the backbone of many parts of the west is people who are so low or three, four, five people. our job is to help them and give the management software, keeping track of the record and give them the ability to purchase as well as any of the large enterprises. >> is a challenge to make them into good business people. >> we have done very well with this. we have brought in equipment that is thidigitized. we have digitized x-rays and the like. this is enormously viable for a physician to survive. > do you have to forestall any acquisitions? >> no, we are well financed. we have a cash balance of about $250 billion. we have a line of credit of 400 billion and we generate about $250 billion a year. >> your growth machine. will you ab-- you are a growth machine. >> we have some things in the pipeline and we expect some good growth this year. >> we have to go, we will talk again and see how the new administration is doing. thank <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=812868&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=812868&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Business,Health,Careers & Occupation,Medical http://player.clipsyndicate.com/view/367/819382 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/819382?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2009/1/26/58/351/5ee2f3e5-a67a-4ac9-95e4-2cb8965c4bfe_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Pfizer Buys Wyeth for $68 Billion - Live! From Pfizer's HQ in New York, NY: Interview with Chairman/CEO Jefferey Kindler</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/819382?cpt=8&wpid=98 Mon, 26 Jan 2009 15:53:14 +0000 Spotlight: Pfizer Pfizer Buys Wyeth for $68 Billion - Live! From Pfizer's HQ in New York, NY: Interview with Chairman/CEO Jefferey Kindler http://www.clipsyndicate.com/video/playlist/367/819382?cpt=8&wpid=98 Bloomberg the largest pharmaceutical acquisition and almost five years, pfizer says it was bought -- it will buy wyeth for $68 billion. jeffrey kindler fresh from a news conference. >> the news conference just ended. i am here with a jeffrey kindler, the ceo of a newly- emerging pfizer. obviously it began for the company. shares are down right now by about 8%. shareholders a little wary about the deal, the merger. some would say that this is a good opportunity for pfizer to slim down and be more nimble. why did you choose another path? >> we have spent the last two years making the company nimble, stronger, leaner, more disciplined. we demonstrated we are our commitments. we're in a position that we can see is what is really a unique opportunity to create the world's premier pharmaceutical company. and match between these two companies -- with the businesses and the products they provide, the great science but goes on, absolutely great. >> i had an analyst on earlier that says it kind of takes care of the lipitor problem, of course, that drug being taken off patent. do you agree? >> it meaningfully addresses that. one of a very exciting things about this, is we can provide investors with a lot more clarity about what this company looks like as we go into the future the real exciting thing is how the birds by the company will be over the next several years. we will be in consumer health, animal health, nutrition. we will be the no. 1 primary care, number two specialty care, on our way to becoming the no. 3 biotechnology company. we are addressing significant diseases are around the world. no. 1 in just about every market we compete in. just a terrific combination and great for the patients. >> future acquisitions? >> i do not think we will do another $68,000,000,000.10 this week. clearly the benefits of the combination -- over time we will have a terrific financial strength. we can have an enormous operating cash flow, strong credit profile. we will be over time in a position to do what we need to do. we will then invest in our business and make sure it goes forward. >> how long do you think integration will take? > we will go as quickly as we can. we will be ready when the closing comes to move quickly and to integrate. we learned a lot from prior transaction about what works and doesn't. we know most importantly how critically important it is to preserve our science, to ensure that our scientists doing what they're doing and did not get disrupted by this. and we will go about this with speed and fairness and combine the two great company to effectively. >> if the economy continues to deteriorate, you think you will have to look again at the staff structure and look and r&amp;d to see if you have to cut down again? >> we are trying to create a company that is resilience to address and the operating environment. long before the recent tour moral of the last several months and management -- turmoil of the last several months we announced almost exactly two years ago this week about we would take a significant cost out of the company and we rejected by the end of 28 we will take out $1.5 billion up to $2.5 billion. we announced this morning we've substantially exceeded the goal and achieved $2.8 billion. we are building a strong, flexible lean discipline company that we think will be successful in every operating environment. >> what do you say to those who say even with the deal, it doesn't exactly address the pipeline? how do you address the new drugs? >> both companies have a terrific pipeline of drugs in a whole host of diseases areas and they are very complementary. both companies, for example, addressed a great deal to address the plight of alzheimer's -- one of the most serious and debilitating diseases. we think it's my r&amp;d organization are complementary and can support each other and we will have a pipeline second to none and we will have the resources to advance the pipeline and take the medicines to patients as quickly as we can. >> thank you for joining us. jeffrey kindler, ceo of pfizer. monica, back to you. >> thanks. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=819382&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=819382&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:PFE, NYSE:WYE Law & Legal Issues,Health,Business,Economy,Pharma,Bio-tech,Government & Politics,Editors Pick http://player.clipsyndicate.com/view/367/797193 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/797193?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2009/1/5/71/364/28a5936a-bf8b-44df-9a93-54c5bfb4bbca_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;"></td></tr></table> http://www.clipsyndicate.com/video/playlist/367/797193?cpt=8&wpid=98 Mon, 05 Jan 2009 00:00:00 +0000 Pharmaceutical Industry Puts Moratorium on Pharmacy Freebies http://www.clipsyndicate.com/video/playlist/367/797193?cpt=8&wpid=98 WAGA FOX 5 Atlanta, GA <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=797193&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=797193&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Business,Pharma http://player.clipsyndicate.com/view/367/791820 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/791820?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/12/29/130/448/eb407091b69c2cabc3c76e1342472b0c_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">ALLERGAN ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF LATISSE™ -- FIRST AND ONLY TREATMENT APPROVED BY THE FDA FOR HYPOTRICHOSIS OF EYELASHES</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/791820?cpt=8&wpid=98 Mon, 29 Dec 2008 17:48:00 +0000 ALLERGAN ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF LATISSE™ -- FIRST AND ONLY TREATMENT APPROVED BY THE FDA FOR HYPOTRICHOSIS OF EYELASHES - Video ALLERGAN ANNOUNCES U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF LATISSE™ -- FIRST AND ONLY TREATMENT APPROVED BY THE FDA FOR HYPOTRICHOSIS OF EYELASHES http://www.clipsyndicate.com/video/playlist/367/791820?cpt=8&wpid=98 MultiVu <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=791820&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=791820&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Allergan, FDA, LATISSE, Eyelash, hypotrichosis, treatment, bimatoprost, prescription, inadequate, eyelashes, length, thickness, darkness, YWpvb29u, 36439, MultiVu Entertainment,video http://player.clipsyndicate.com/view/367/793930 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/793930?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/12/31/58/351/03652042-a8b1-4a8e-9b0d-2c507ae0465d_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Outlook for Pharmaceuticals - Interview with CFO Luke Beshar</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/793930?cpt=8&wpid=98 Wed, 31 Dec 2008 15:42:18 +0000 Spotlight: NPS Pharmaceuticals Outlook for Pharmaceuticals - Interview with CFO Luke Beshar http://www.clipsyndicate.com/video/playlist/367/793930?cpt=8&wpid=98 Bloomberg it has been a very rough year for companies and investors, but shares of nps pharmaceuticals up 60%. how is it managing to thrive in a recession and what we expect in the pharmaceutical industry in 2009? let us bring in their chief financial officer, lori beshar -- luke beshar here in our studio. what are you guys doing right about the market perhaps the not see the last four years? >> it started in late 2007 when we restructured the business. we completed it in the beginning of 2008, and we began the year in a good position with a strong cash position, very secure. we had a very talented and experienced and motivated management team and a new strategy. we launched in the latter half of the fourth quarter of this year, two phase three studies for compounds. the strategy revolves around identifying products that are niche products, typically intestinal disorders. little or no competion, typically in the u.s. >> let's talk about the impact of this out performance you have had. in a down year for the market, your stock is up, as we said, 60 percent -- is there more exposure to your company, and will benefit? >> it has given us a lot more exposure. we executed on virtually every aspect of our business plan. and people are starting to take notice. we have a two-pronged business approach, and people are starting to understand. in drug development, we have a niche strategy, away from primary care and looking toward specialty-care physicians. the value creation opportunities. we are finding niches and products in areas where a large pharma does not play in. in our will to portfolios, we partner products but are not core to our competence -- competencies, we partner with large companies, for example, like amgen. one product is being sold by amgen, growing 30% to 40 percent a year, will be a blockbuster drug, and in 2012 or 2013, will to use to nps. so a nice balance with inherently high risk profile but also gives us predictable royalty stream to balance it out and we kind of like that balance. frankly, i think investors are starting to tech notice. >> very briefly. you guys have five analysts covering your stock. analyst coverage is one of the big complaints for small caps. >> we do expected to rise. a number are seeking as out. yes, we do. >> thank you. chief financial officer @ nps pharmaceuticals. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=793930&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=793930&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NASDAQ:NPSP, NASDAQ:AMGN Law & Legal Issues,Health,Business,Economy,Pharma,Bio-tech,Editors Pick http://player.clipsyndicate.com/view/367/772522 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/772522?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/12/8/58/351/6d4d78b0-151c-4d45-92b3-a17d50c25dba_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Health of the Drug Industry and the Future of Healthcare - Interview with CEO Sol Barer</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/772522?cpt=8&wpid=98 Mon, 08 Dec 2008 14:48:36 +0000 Spotlight: Celgene Health of the Drug Industry and the Future of Healthcare - Interview with CEO Sol Barer http://www.clipsyndicate.com/video/playlist/367/772522?cpt=8&wpid=98 Bloomberg celgene, accompanied the makes a cancer drug, is one of the top- 10 performers in the s&amp;p for the year. while the s&amp;p has lost 40 percent this year, celgene has gained 17%. the ceo joins us from san francisco where he is attending the american society for hematology conference. thank you for taking time to be with us. >> thank you. pleasure to be here. >> i know this is a major conference. what is the biggest topic among discussion? >> several really exciting things that are occurring. we are very fortunate. this has been the most successful american society of hematology meeting. over 150 abstracts, really good news for patients with blood cancers. other drugs being highlighted. really a very exciting time. > talking about the markets and the economy -- has that been the biggest concern or topic of discussion there? >> buzz always in the background. but this is really more a clinical scientific meeting where physicians from around the world come to hear the latest information. so for us, it is a very important meeting and gives us an opportunity to really focus in and talk about them and talk about all the new things that are very relevant to patients. >> i want to talk more about that, of course, but we only have a little bit of time in this section. tell me, how is your own company navigating the financial crisis? >> we are in a very fortunate position. we provide life-saving drugs and we have been financing the strong. we have a positive cash flow. as you mentioned, we performed very well and we are expanding around the world. these are not easy times for any company, but in the current environment, we are in a very good position. in terms of the goods about we offer, are very important to patients. and we are very pleased with it, and we are financially strong. >> we will talk more about that after the break. and we will also discuss the changes in the health-care industry and how that will impact his company. keep it here. >> back with a celgene the ceo sol barer joining us from san francisco. you were talking about a strong cast position of your company, but i'm wondering if you are comfortable with your eps forecast right now, and you expect to have to pare back any spending? >> i think in times like this, one always has to be cautious. but we generally take a long term view. i think the key is indeed to have a long-term view. unless we develop life-saving therapies to patients, we did not add much value to society, and that is what we do. so we tend to look for the longer-term perspective. we invest significantly in research and development. because of that we have been fortunate in bringing drugs to the marketplace. we are also working on many new drugs that i think can have a significant impact. but that has a long-term perspective. >> short-term you are comfortable with your cash position? >> we generally will update that at the beginning of this year, as we talk about 2009 and sort of where we see ourselves landing in 2008. >> want to talk about drugs, of course. recently you won clearance for placental visit placenta stem cell research for crones disease, but looking at the market, it is quite crowded. is it wise to get into a crowded market at this point? >> one of the divisions we have with those themselves, an entirely new area for medicine and we are a broad awaiting the unique therapeutics in a variety of occasions. the first one is crohn's disease, unique attributes. it is far from assured, and as patients tell you, there is a lot that needs to be done. and after that we have plans to expand into other implications like multiple sclerosis. to really change the paradigm of treatment for a number of those diseases. >> tell me about your reaction on generics. barack obama coming in, he will change some of the rules. and also medicare payments -- how will that impact a company like yours? >> medicare is an important part, obviously, of the population we serve, because cancers are generally diseases of older individuals. it does impact us. but we are in a very fortunate position because we have you need drugs that provide unique benefit and which are life- saving benefits. i think the value that we bring is very important to patients. at this meeting there were reports in terms of the ability to extend life and multiple myeloma, a big impact in non hodgkin's lymphoma. i think we are in a very fortunate position from that respect. >> thank you for taking the time to talk with me. sol barer, c zero of celgene. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=772522&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=772522&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NASDAQ:CELG Law & Legal Issues,Health,Business,Economy,Pharma,Bio-tech,International,Government & Politics,Editors Pick http://player.clipsyndicate.com/view/367/776261 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/776261?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/12/11/58/351/e4c6d0e3-f5df-4ef6-91e0-5836a641d7ae_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Eli Lilly Lowers 2009 Forecast - Live! From New York Headquarters: Interview with CEO John Leichleiter</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/776261?cpt=8&wpid=98 Thu, 11 Dec 2008 12:43:53 +0000 Spotlight: Eli Lilly Eli Lilly Lowers 2009 Forecast - Live! From New York Headquarters: Interview with CEO John Leichleiter http://www.clipsyndicate.com/video/playlist/367/776261?cpt=8&wpid=98 Bloomberg we have been talking about the 2009 forecast for eli lilly. the drug maker lowered its forecast. julie hyman sat down with john lechleiter, ceo of eli lilly. >> thank you very much. we have been looking at the forecast for next year and looking at the full-year expectations for imclone as well. with the forecast, we have seen a change in sentiment about the drug makers, which have been seen for so long as more recession-proof. what is changing in your industry? > i have said all along, we're not recession-proof. we will be less affected than others by the changes in the macro economy. there are a lot to moving parts. next year, all of our companies will be changing due to the exchange rate. we have questions about health reform in the u.s. we have a question of when our new cardiovascular drug will improve. the biggest move in part for us is the incorporation of imclone. we haven't given guidance before the acquisition and then baking in the acquisition. we took a charge of 30 cents to 35 cents a share for that acquisition. >> if you take out the charge of that acquisition, how effective are you by exchange rates worsening in the economy? >> we are well hedged. a strengthening dollar means overseas sales will be less. expect to see sales growth coming down, as reported. on the other hand, it helps manufacturing gross margins. it balances out fairly well. on the upside, we see continued, decent volume growth next year. through three quarters, we have reported 12% top line growth. 6% of that came from volume. we still see good growth from many of the nine products that we have launched this decade. if we are able to launch the cardiovascular drug next year, we will be a will to wrote the story. -- that story will grow. >> it sounds like it will take a while to do. >> the so-called medical management studied -- in other words, people who have acute coronary syndrome, but would not receive a step. we're now getting reviewed by the fda and european authorities. >> i also want to talk to you in little bit more about the acquisition of imclone. you said you are open to making future acquisitions. how aggressive will you be? there are not a lot of deals in this environment. >> a lot of people say that imclone is aggressive as it gets. we are very pleased with that acquisition. we could have as many of the three of their antibodies in trials next year. and of course, erbitux nicely complement our two chemotherapy drugs. you can expect that we will continue to be active. > health care reform, what are your expectations from the new administration? >> we are fairly upbeat and positive for the potential. and means of health-care. pharmaceutical medicines are 10%. we know that 10% keeps people out of the hospital and get people back to work. >> unfortunately, we are out of time. thank you very much for speaking with us today. back to you. >> thank you, john lechleiter, ceo of eli lilly talking to julie hyman. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=776261&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=776261&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:LLY, NASDAQ:IMCL Law & Legal Issues,Health,Business,Economy,Pharma,Bio-tech,Government & Politics,Editors Pick http://player.clipsyndicate.com/view/367/772898 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/772898?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/12/8/200/551/9bb7bec9-0987-4358-bdf8-fea223814496_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Former employees of Pfizer are bringing new jobs to the Wabash Valley.</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/772898?cpt=8&wpid=98 Mon, 08 Dec 2008 23:11:54 +0000 Former Pfizer employees bring new jobs to the area Former employees of Pfizer are bringing new jobs to the Wabash Valley. http://www.clipsyndicate.com/video/playlist/367/772898?cpt=8&wpid=98 WTHI CBS 10 Terre Haute are bringing new jobs to the wabash valley. compliance laboratories l-c" will provide testing services for businesses in the pharmaceutical and food industries. after pfizer closed its terre haute facility.. some employees left the area to find jobs. five decided to stay.. and to bring jobs "back" to vigo county. the company received start-up funding from the "terre haute innovation alliance" because of the opportunities it brings to the area. one of the founders says it has been a team effort.. and many are counting on the success of the business. "everybody in the community has, has come together in a lot of different ways to help us.. to make sure that we are going to be successful" "midwest compliance labs" hopes to begin offering testing services in january. an seminar is comi the co to digital <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=772898&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=772898&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> pfizer, employees, jobs, Midwest Compliance Laboratories News,Local News http://player.clipsyndicate.com/view/367/747389 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/747389?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/11/13/58/351/f67e2536-13ca-47d1-818f-ca71532afa3a_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Report and analysis by Lindsey Arent of Bloomberg News</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/747389?cpt=8&wpid=98 Thu, 13 Nov 2008 02:13:45 +0000 Health-Care Reform On The Hill Report and analysis by Lindsey Arent of Bloomberg News http://www.clipsyndicate.com/video/playlist/367/747389?cpt=8&wpid=98 Bloomberg x democrats are waiting for the president to take power before pushing for the change to the health care system. -- >> democrats are waiting for their next president. >> with the release of the 87 page called the action plan, mike baucus fired the first salvo which is going to be a difficult debate over health care. the finance committee has different ideas about how to fix what is the problem with the health care system. >> the health-care system is broken for many americans and it is straing our economy. there is no way to solve the economic troubles by fixing the health care system. >> he said his that has been working closely with obama on the plan and a share a vision for reform with one exception. his plan would require mandatory health coverage for all americans. this includes guaranteed coverage regardless of facing illness, an insurance exchange for people can buy coverage and temporary expansion of medicare for americans ages 55-64. employers that do not offer coverage would have to contribute to 8 coverage fund. there would be a cap on tax exclusion. some wonder if congress can pass such a health care reform. >> there is a complexity of the plan and the cost and this is what we have to look at. there are many moving parts to any health reform proposal. it affects a huge part of our economy. >> while mike baucus did not offer details for a revenue source, he said the cost to the country would be far greater down the line if help was not enacted right away. >> we have no choice. the longer we wait, the longer the inaction, the greater the cost. >> they would like to have acted upon by the first half of next year. given the high profile of this and so many lawmakers involved, this could be easier said than done. chief amongst the people who want to have a role in this is senator edward kennedy. he supports this plan that i am sure he will want to have a plan of his own. that is what we are hearing. >> thank you so much. i <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=747389&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=747389&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Business,Bloomberg Business News http://player.clipsyndicate.com/view/367/748699 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/748699?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/11/14/17/98/471ccd53-7e76-4dab-ae8c-dafcf6126e90_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Doctors in Germany say a patient appears to have been cured of aids. Governor Mike Beebe gets involved with story time to encourage children at the Little Rock Pediatric Clinic to read school unprepared. How to deal with braces as an adult. </td></tr></table> http://www.clipsyndicate.com/video/playlist/367/748699?cpt=8&wpid=98 Fri, 14 Nov 2008 03:51:34 +0000 Family Healthcast: Possible cure for AIDS Doctors in Germany say a patient appears to have been cured of aids. Governor Mike Beebe gets involved with story time to encourage children at the Little Rock Pediatric Clinic to read school unprepared. How to deal with braces as an adult. http://www.clipsyndicate.com/video/playlist/367/748699?cpt=8&wpid=98 KLRT Fox 16 Little Rock <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=748699&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=748699&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Local News,Health,Alternative Health,Government & Politics,Public Health,Careers & Occupation,Medical,HIV http://player.clipsyndicate.com/view/367/749123 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/749123?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/11/14/58/351/94e12c1d-1a82-4614-9402-87073dfbffbf_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Interview with CEO William Sullivan</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/749123?cpt=8&wpid=98 Fri, 14 Nov 2008 15:41:15 +0000 Spotlight: Agilent Technologies Interview with CEO William Sullivan http://www.clipsyndicate.com/video/playlist/367/749123?cpt=8&wpid=98 Bloomberg agilent technologies had a 28% jump in earnings. the biggest maker of scientific testing equipment and the world -- to cost cuts that were better than last minute. see all william sullivan joins us with more. welcome to "market pulse." agreed to be here. >> of course we talked about the positive side but we have to be jumping quickly to the negative side. your forecast was below estimates. i know a large portion of your business is electronic measurement. is the forecast a result of what we are seeing in terms of consumer electronics the man? >> absolutely. first of all, we are taking a very conservative position as we move into the fiscal 2009. 12 percent of the company is related to semiconductor consumer related products. as we noted in many of your newscasts, there is a major pullback in consumer spending that is driving less capacity in manufacturing, particularly in asia. >> another part of your business, life sciences, quite reliance on that industry. i use in about hold up better? how are the different segments balancing in this environment? >> that really is the strength of agilent technologies, a very broad measurement solution provider applied to many markets around the world. in the life science area, business grew 17%. focus on academic and research providing measurement tools for the understanding and cure of diseases grew 22%. we have a strong product portfolio and very well positioned even though there are a lot of issues related to large pharmaceutical companies around the world. >> since electronic measurement is a bigger portion of your revenue at this time, when you look into the future -- we have been talking to a lot of folks about this -- when you see potential recovery in consumer electronics and demand for other types of electronic question of >> a great question. conventional wisdom is the middle of next year we will hit bottom and see recovery in the second half of 2009. quite frankly we do not know what will happen, given no one has seen this type of economic situation in decades. so, what we need to do is focus our energy where business is. we are a leader in long-term evolution, next generation of cellphones,. focusing on are in the opportunities, electronic surveillance in the war against terrorism. and what we want to do is shift our resources to where there is opportunity and execute and meet our customers' needs. >> you also have been cutting costs. more of that is to, going into the middle of next year. do you foresee any job cuts? we heard from so many companies doing that right now. >> fortunately we started to take action in third quarter of fiscal year 2008. we learned our lessons from the year 2000. we slowed down hiring dramatically. and we have fought discretionary expenses and focusing on where there are business opportunities. we made announcements of curtailing salary increases in 2009. so we are very well positioned to be able to weather a recession will then forward. you can never say never, but we have taken the actions required to try to assure the employees are focusing on business opportunities and not worried about their jobs. >> talking about different segments of their business. i quickly want to touch on aerospace. we heard from boeing, delaying the delivery of one of its planes. how is that segment doing and how big of a part of the business is it? >> aerospace and defense is a large part of the business. we do provide measurement solutions for electronic warfare as where as maintenance. aerospace and defense was flat year over year. the appropriations process clearly slowed down, being an election year. and i think we will have to wait and see how the aerospace and defense market plays out in 2009. as i mentioned, though, we are shipping to surveillance, focusing on homeland security, and we believe we can make a real contribution in this area. >> bill sullivan, thank you very much for joining us. >> thank you. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=749123&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=749123&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:A Law & Legal Issues,Shopping & Commerce,Business,Military/Defense,Technology,Telecom,Consumer Electronics,Science & Technology,Hardware,Editors Pick http://player.clipsyndicate.com/view/367/747329 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/747329?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/11/13/91/384/34ff0ac7f74c629b72d48d9546e73c69_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">There are 40-thousand clinical trials going on in the United States right now and more than a million people are taking part in them. That's more people than in the state of Alaska. All participants hope for a breakthrough that will save their life and the lives of others, but is the risk worth it?</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/747329?cpt=8&wpid=98 Wed, 12 Nov 2008 13:11:15 +0000 Clinical Trials: At Your Own Risk There are 40-thousand clinical trials going on in the United States right now and more than a million people are taking part in them. That's more people than in the state of Alaska. All participants hope for a breakthrough that will save their life and the lives of others, but is the risk worth it? http://www.clipsyndicate.com/video/playlist/367/747329?cpt=8&wpid=98 KMGH ABC Denver <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=747329&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=747329&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Law & Legal Issues,News,Local News,Health,Alternative Health,Legal,Government & Politics,Public Health http://player.clipsyndicate.com/view/367/748103 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/748103?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/11/13/91/384/c7c74b111d92cba6724bffd9e21e3270_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">A clinical trial at National Jewish Health uses less invasive procedure to help emphysema patients breathe easier.</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/748103?cpt=8&wpid=98 Thu, 13 Nov 2008 15:13:05 +0000 Emphysema Study Gives Patients Hope A clinical trial at National Jewish Health uses less invasive procedure to help emphysema patients breathe easier. http://www.clipsyndicate.com/video/playlist/367/748103?cpt=8&wpid=98 KMGH ABC Denver <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=748103&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=748103&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Local News,Health,Alternative Health,Hospital,Government & Politics,Public Health http://player.clipsyndicate.com/view/367/733162 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/733162?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/10/29/22/289/a3dcc8c1-ad77-46a5-967b-667aa0dbe2e2_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">The East Syracuse-Minoa school district and Bristol Myers Squibb have teamed up for a new program called Research: The Educational Journey.</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/733162?cpt=8&wpid=98 Wed, 29 Oct 2008 16:56:01 +0000 ES-M part of new pharmaceutical program 10/29/08 The East Syracuse-Minoa school district and Bristol Myers Squibb have teamed up for a new program called Research: The Educational Journey. http://www.clipsyndicate.com/video/playlist/367/733162?cpt=8&wpid=98 WSYR ABC 9 Syracuse <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=733162&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=733162&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Local News http://player.clipsyndicate.com/view/367/739008 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/739008?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/11/5/58/351/778fb5a2-fa40-4481-8333-e38d078d7d17_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Analysis by Bruce Downey, Barr Pharmaceuticals CEO; Analysis by Neil Koehler, Pacific Ethanol CEO</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/739008?cpt=8&wpid=98 Wed, 05 Nov 2008 03:16:36 +0000 Generic Drug Industry: What's At Stake?; Election 2008 & Health Care; FDA Regulation Analysis by Bruce Downey, Barr Pharmaceuticals CEO; Analysis by Neil Koehler, Pacific Ethanol CEO http://www.clipsyndicate.com/video/playlist/367/739008?cpt=8&wpid=98 Bloomberg tonight's results from the business sector. we will talk to two c.e.o.s from diferent industries, both directly impacted by decisions in washington. first, i'm joined by bruce downey, c.e.o. of barr pharmaceuticals, the company in the process of being acquired by the largest generic drugmaker. we appreciate you being with us on this busy election night. let me ask you, first of all, your impression of what is going on tonight and what is at stake for your business? >> well, the good news for our industry is that both senator obama and senator mcain are pro generic, so from the generic drug perspective, either would be a big improvement for the industry. they support generic substitution and generic legislation and a stronger f.d.a. generic drug ofice. across the board, either way, i think our industry has gone very well this evening, and in a separate matter, both candidates favor stem cell research, which will be a big change from the current administration and one that i think is very positive for the industry and very positive for the country. >> for the generic industry versus the brand name drugmakers that we all know around the country, there has been a lot of talk about president obama perhaps cracking down on the drug business, but from a generic perspective, you see it as an oportunity? >> i think it will be a more positive environment for us over the next four years either way, for the reasons i said. for us, the biggest single isue is the passage of generics bio-legislation, and the legislation doesn't apply to b o logics and as they bem a bigger part of the medicine chest of the country, it is important we pas legislation for as a pathway for biologics and i think we will se that in the next few years. >> you loo recall that senator clinton pushed hard for the generic biologics legislation moving forward. do you think that will move quickly in the next congress? >> i actually do. i think senator clinton will be a big advocate for. that unfortunately, neither senator obama nor senator mcain are active on the committees of jurisdiction that address our issues. senator clinton is. she has been a big advocate in the past and we look forward to working with her in the future to see this legislation become law. >> are you worried at al about the talk of the national healthcare proposals coming from senator obama? senator mccain had a different proposal. do you see senator obama's proposal, basically a national healthcare plan taking a bite out of generics? >> well, i think that the more insurance coverage you have, the more of the generic drugs become a part of the medicine chest of the country. i think it's a very positive environment for us. coverage means acces means sales for us. we're loking forward to working with the congress to expand coverage and to se more people have access to our medicine. >> what about the regulatory front? you mentioned the f.d.a. and there has been criticism of the f.d.a. perhaps a greater regulatory hand coming from the f.d.a. in the future. does that pose potential risks for your country? >> the f.d.a. has been unfairly criticized recently. it's true we need more foreign inspection in the pharmaceutical manufacturing abroad but the f.d.a. hasn't been given the resources to accomplish that. i think we should work with the next congress and administration to make sure that happens, and i think that the f.d.a. will respond to that challenge. i think a separate chalenge is that generic drugs ned additional resources to process the requests they're receiving. we look forward to working with the congress and the new administration to seeing that happen. >> do you see democrats in congress -- you talked about the fact that drugs an drug ingredients are coming in from overseas. do you see that as a potential limitation on your business going forward, generics and brand name drugmakers loking over seas for so many of their ingredients? >> that's true. we do look overseas for ingredients, in part because it's so difficult to get pharmaceutical plants approved in the u.s. so i don't see that changing, but i do think that it's appropriate that they receive the same sort of inspection scrutiny we receive in the united states and i think the congress is in the process of addressing that problem. it will be addressed in the next two years. >> bruce downey, the c.e.o. of barr pharmaceuticals joining us to give us perspective from the healthcare industry of what's playing out tonight on election day in america. we appreciate you joining us. >> thank you. >> now perspective from another industry with a stake in this race for the white house,the renewable fuels industry, neal kohler, thank you for joining us. john mccain has never been a big supporter of ethanol. does that leave you celebrating the results right now? of course, barack obama coming from illinois, an ethanol state. >> peter, i would say we have always had very strong bipartisan support for ethanol from democrats, republicans, this president, and also from the congress, and it is really from the congress of the united states where most of the policies that have helped develop this industry and fueled a very dramatic growth in this business to whereby the end of this year we will be supplying 7, 8% of all the gasoline in the united states, so from that standpoint, it hasn't realy mattered who was president but clearly there has been a distinction between senator obama and senator mccain. senator obama has been much more proactively in support of moving us in the direction of more energy dependence and energy security and reducing co2 emissions antiing those all together in a renewable fuels policy. from that standpoint, we are encouraged to see that he is heading to the be the next president of the united states. >> right now, we have a federal mandate for the expanded use of ethanol, 36 billion gallons by 2032 as i recall right now. do you have any hope that senator obama, if he is the next president of the united states would actually expand that mandate? >> yes, we do. in his campaign platform, he had an objective of growing that to 60 billion gam lons -- lal gones by 203o we think that is achievable. we can build on the success that the corn ethanol industry has laid out and convert cellulose and a wide range of biomass into ethanol and other biofuels and we think that is entirely achievable. in fact, it's absolutely imperative that we do something much more significant than we have done today to reduce our dependence on oil and to move us in the direction of energy independence. >> neil, as you know, we are seeing oil prices retreating. we're seagoing, of course, a glut of ethanol on the market right now. your sense right now, the outlook for your business right now, given what's going on in the marketplace, there's a lot of americans who might not be as concerned about gasoline prices going forward, simply because they're coming down. >> well, whether we have $65 a barrel oil or $160 barrel of oil, the fact remains we are not running out of the product with a global demand that continues to grow for the product, but we are increasingly dependent on a very unstable parts of the country -- of the world for that oil. today is a good example. the price of oil went up over $6 today because saudi arabia announced they were going to not produce 900 million barrels per day. these are significant events that in one day can cause major changes in the overall supply/demand balance on oil, so we need to keep a view towards the long term, and that is what the policies, renewable fuel standards and advancing that can do for us. >> should the results tonight make investors more interested in companies like yours? >> absolutely. when you lok at the infrastructure needs of this country, the need to have -- to be able to combine economic development with good environmental initiatives is a very positive future for companies like ours and industries like ours that are providing that kind of integration of good, clean, energy, economic development, and environmental protection. >> neil, let me you ask one final question. there has been a push from senator obama and others about the need for this country to tighten its belt right now. can your industry go without the tax subsidies, the breaks coming from the federal government and still survive? >> we have said if we were to level the playing field and take away all the subsidies for all energy industries, specifically in this case the oil and ethanol industries, we would be as competitive if not more competitive. our product is cheaper than gasoline. it's providing the only opportunity to have meaningful co2 reductions from transportation fuels, and with climate change being the largest environmental issue facing this world today, our future <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=739008&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=739008&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Business,Pharma http://player.clipsyndicate.com/view/367/710659 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/710659?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/10/3/125/443/144ab8ce-156a-476e-965f-aa5d3763970c_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;"> Wayne, New Jersey, September 15, 2008 - Bayer HealthCare Pharmaceuticals Inc. today announced that Betaseron (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections.</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/710659?cpt=8&wpid=98 Fri, 03 Oct 2008 15:32:29 +0000 Betaseron to Offer the Thinnest Needle in Multiple Sclerosis Wayne, New Jersey, September 15, 2008 - Bayer HealthCare Pharmaceuticals Inc. today announced that Betaseron (interferon beta-1b), its treatment for relapsing forms of multiple sclerosis (MS), will soon be available with a new 30-gauge needle, which will be the thinnest needle of any injectable disease-modifying therapy for people with MS. The new needle is as thin as the needle commonly used for insulin and pediatric injections. http://www.clipsyndicate.com/video/playlist/367/710659?cpt=8&wpid=98 News Broadcast Network <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=710659&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=710659&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Entertainment http://player.clipsyndicate.com/view/367/712567 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/712567?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/10/7/8/414/b9704a3c-3808-4cba-bfcd-3a688c47a3aa_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">It most often strikes women...but more and more...men are being diagnosed with lupus.</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/712567?cpt=8&wpid=98 Mon, 06 Oct 2008 23:03:53 +0000 UR Research -- New Balm for Lupus It most often strikes women...but more and more...men are being diagnosed with lupus. http://www.clipsyndicate.com/video/playlist/367/712567?cpt=8&wpid=98 WHAM ABC 13 Rochester <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=712567&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=712567&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Local News http://player.clipsyndicate.com/view/367/697564 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/697564?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/9/18/44/336/3e34418308047ea25f8a93b4ee27e6f2_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Pfizer's new Web site allows patients to check for drug interactions.</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/697564?cpt=8&wpid=98 Thu, 18 Sep 2008 10:08:16 +0000 New Site Allows Patients To Research Drugs Pfizer's new Web site allows patients to check for drug interactions. http://www.clipsyndicate.com/video/playlist/367/697564?cpt=8&wpid=98 KPHO Phoenix, Arizona <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=697564&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=697564&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Business,News,Local News,Health,Pharma,Science & Technology,Internet http://player.clipsyndicate.com/view/367/695463 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/695463?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/9/16/4/3/22ae0cdb-04f9-4a98-b24b-63cc3cd62b86_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Though branded a 'major pollutant' by the government, an AP Investigation found that more than 100,000 tons of pharmaceutical waste is dumped each year by the health-services industry, largely down drains. (Sept. 15)</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/695463?cpt=8&wpid=98 Mon, 15 Sep 2008 19:12:23 +0000 Keeping Drugs Out of Water Supply Though branded a 'major pollutant' by the government, an AP Investigation found that more than 100,000 tons of pharmaceutical waste is dumped each year by the health-services industry, largely down drains. (Sept. 15) http://www.clipsyndicate.com/video/playlist/367/695463?cpt=8&wpid=98 Associated Press <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=695463&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=695463&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> pharma-water News,Health,Government & Politics,Politics - U.S. http://player.clipsyndicate.com/view/367/671815 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/671815?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/8/19/130/448/2ae94897b4030d9e3d1243b48c9aebec_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">The Shifting Landscape of Health Care Fraud and Regulatory Compliance</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/671815?cpt=8&wpid=98 Tue, 19 Aug 2008 14:16:00 +0000 The Shifting Landscape of Health Care Fraud and Regulatory Compliance - Video The Shifting Landscape of Health Care Fraud and Regulatory Compliance http://www.clipsyndicate.com/video/playlist/367/671815?cpt=8&wpid=98 MultiVu <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=671815&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=671815&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Deloitte, Forensic, Center, DFC, health, care, Fraud, GDP, Regulatory, Compliance, investigations, criminal, civil, amtvYGBp, 32650, MultiVu Entertainment,Emergencies & Disasters,Crime,Fraud http://player.clipsyndicate.com/view/367/671830 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/671830?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/8/19/58/351/3c34f971-4bb7-4cd5-9a35-d4795f4350aa_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Diabetes Drug Byetta Linked to Two Deaths of Patients with Pancreatic Cancer, Sending Shares of Amylin and Eli Lilly Down</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/671830?cpt=8&wpid=98 Tue, 19 Aug 2008 19:30:00 +0000 Healthcare News: Lingering Concerns About Byetta Diabetes Drug Byetta Linked to Two Deaths of Patients with Pancreatic Cancer, Sending Shares of Amylin and Eli Lilly Down http://www.clipsyndicate.com/video/playlist/367/671830?cpt=8&wpid=98 Bloomberg investors continued to dump shares of amylin pharmaceuticals. the stock fell the most in seven years yesterday on safety concerns about its diabetes drug. suzanne l. howland picks up the story. >> thank you. investors are continuing their stance on amylin and the partner, eli lilly. both lower today. the drug was connected to two deaths in patients with pancreatic inflammation. the fda is seeking stronger warnings for the drug. their differing views on wall street about the future of the drug. piper jaffray says the stock sell-off as an overreaction because the company has discussed the risk associated with pancreatic disease. analysts said canaccord adams and a stanford research are less optimistic saying sales are brisk and the drug may have a higher risk profile and doctors may not want to prescribe it. this is not the first time amylin has made news in recent weeks. july 31, is search the most in three years on takeover speculation. investor carl icahn is among the largest investor for the company and is currently trying to work out a deal with its other large holding, imclone. a lot of speculation about bristol meyers. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=671830&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=671830&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NASDAQ:AMLN, NYSE:LLY, NYSE:BMY News,Business,Law & Legal Issues,Health,Diabetes http://player.clipsyndicate.com/view/367/665492 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/665492?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/8/11/58/351/eab341ae-2d2d-44c8-8e2f-b70d7cb432ac_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Analysis by Scott Gottlieb, Former Deputy Commissioner of FDA</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/665492?cpt=8&wpid=98 Mon, 11 Aug 2008 16:46:00 +0000 Health Care In Focus: Political Analysis On Health Care Analysis by Scott Gottlieb, Former Deputy Commissioner of FDA http://www.clipsyndicate.com/video/playlist/367/665492?cpt=8&wpid=98 Bloomberg is one industry that will clearly be affected by the results of the presidential election. is managing director of the health care investment fund and resident fellow at of the american enterprise institute and former deputy commissioner of the food and drug administrator. thank you for coming in. does either can't predict candidate have a specific agenda where you can say -- does either candidate to have a specific agenda? >> i think it will be the impact of the congressional agenda. if the democrats control all three branches of government, you will see the congressional agenda, and to fruition and that could have a impact on specific parts of the health-care industry -- managed care being one, and obviously pharmaceuticals when you look at the specific proposals. >> let us take a managed care sector. one of the central the base is the whether or not we move toward defined benefit or defined contribution, whether or not the government provides benefits to consumers or provides money so consumers can purchase health care insurance. the democrats clearly favor moving in defined benefit, meaning the government will be in charge of health care deliberately -- delivered. they will put pressure on medicare and benefit plans. not throw them over the cliff -- but it will make those plans attractive and you will see decling enrollment and more people moving into public programs. that is clearly on the agenda for congressional democrats. if you see obama on the white house, that will come to four wishes. there is not a lot of money this year to provide a big new entitlement program. some way democrats in congress also regulation of how much of the caustic and pass on. in the near term, they will make health insurance less attractive, more affordable. longer-term they will move more into public programs and create sort of a death spiral for private plans. >> we heard about prescription drug prices. anything on the horizon? >> if the democrats -- control off the branches, you could see regulation of drug prices. it will be very hard for congress to step in a broadly regulate -- even to get the part d program -- even to have it negotiate prices, which is the mantra here in washington. i think the sub sector of drugs that are vulnerable are specialty tier drugs. these are high costs, typically small molecule drugs. so those 40 or so drugs and specialty steel are particularly hon.. the so-called single source drugs. >> anything people are not thinking of, additional spending on r&d or any additional benefits for companies? >> in terms of benefits? i am not sure there will be a lot of benefits for companies in the coming election if the democrats control all three branches are unfortunately, because there is not a lot of focus on that side, the issue of innovation and trying to expand opportunities. you might see more spending on nih. ultimately translates to more opportunities but it is a slow cycle when you have investments lower down and the r&d process. the other thing is resurgence medicare. it will be much more involved in setting what people can get access to. this will affect -- probably it shares of a canadian maker of heart drugs falling today. we will find out what is sending it down. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=665492&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=665492&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Business http://player.clipsyndicate.com/view/367/655814 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/655814?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/29/85/378/91f8adc0-7552-4fc4-b9d4-f1ecff49f87f_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Frequently used drug offers new hope for a form of Melanoma.</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/655814?cpt=8&wpid=98 Tue, 29 Jul 2008 21:06:00 +0000 Health Headlines: Cure For Melanoma Frequently used drug offers new hope for a form of Melanoma. http://www.clipsyndicate.com/video/playlist/367/655814?cpt=8&wpid=98 WSYX ABC Columbus skin cancer isn't only caused by spending too much time in the sun.now a frequently used drug offers new hope for this form of melanoma and as abc6 health reporter susan burton tells us, hope for the one million others who are fighting sun-related skin cancer 3 3 ("the melanoma was actually right here on my upper back, right in the middle.") 3 at age 20, melissa parrelli (par-rell-ee) planned on living her dreams, but it was her nightmare that came true when she heard her diagnosis. 3 ("the doctors translated it to skin cancer and my whole world turned upside down basically.") 3 the sun is to blame for most melanomas, but doctors are now discovering a gene called kit. it can trigger mucosal melanomas to grow in places like the mouth and throat. 3 ("this is the kit expression.") 3 researchers believe an abnormality in the kit gene allows the tumor to grow, but a drug used to treat other cancers, called gleevec, appears to put this type of melanoma in remission. 3 ("the gleevec actually goes in and blocks that gene that's turned on and kind of shuts the switch off.") 3 this is the p-e-t scan of an elderly woman. her melanoma started in her anal area and spread to her abdomen and chest, but after nine months on gleevac, her tumor mass is much smaller. 3 ("this patient went on to get gleevec and had a dramatic response from just a few weeks to the drug, where more than 80 percent of her tumor shrunk.") 3 kit mutations are found in a small percentage of cases, but understanding the gene could unlock the mystery of other melanomas. melanomas.the goal is to use this development to find new therapies for the one in five americans suffering from skin cancer each year. with your health solutions, i'm susan burton abc6 on your side. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=655814&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=655814&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Health,Cancer,Skin Cancer/Melanoma http://player.clipsyndicate.com/view/367/656340 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/656340?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/30/110/421/a47416bff86b832809320ddb6e5f74ab_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">New drug could slow progress of the disease</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/656340?cpt=8&wpid=98 Wed, 30 Jul 2008 10:36:12 +0000 Hope for Alzheimers patients New drug could slow progress of the disease http://www.clipsyndicate.com/video/playlist/367/656340?cpt=8&wpid=98 Press Association UK <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=656340&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=656340&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Health,Alzheimers http://player.clipsyndicate.com/view/367/656851 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/656851?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/30/150/497/39147459-beda-4b8d-ab78-c7599034dc83_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">The government seized more than $24 million worth of unapproved new drugs from St. Louis based KV Pharmaceuticals. Agents said the drugs were made after the FDA told the company to stop production. <a href="http://www.kmov.com/justposted/stories//kmov_justposted_080729_druglist.1588838e.html"<font color="red"><B>Check drug list! </b></font></a></font></td></tr></table> http://www.clipsyndicate.com/video/playlist/367/656851?cpt=8&wpid=98 Wed, 30 Jul 2008 03:13:16 +0000 FDA seize $24 million unapproved drugs from local company The government seized more than $24 million worth of unapproved new drugs from St. Louis based KV Pharmaceuticals. Agents said the drugs were made after the FDA told the company to stop production. <a href="http://www.kmov.com/justposted/stories//kmov_justposted_080729_druglist.1588838e.html"<font color="red"><B>Check drug list! </b></font></a></font> http://www.clipsyndicate.com/video/playlist/367/656851?cpt=8&wpid=98 KMOV St Louis, MO <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=656851&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=656851&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Local News,Business,Pharma,Government & Politics http://player.clipsyndicate.com/view/367/651971 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/651971?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/24/58/351/27bad5f4-063c-4965-a9c1-713e2b101aa4_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Interview with CEO John Lechleiter</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/651971?cpt=8&wpid=98 Thu, 24 Jul 2008 12:14:00 +0000 Spotlight: Eli Lilly Interview with CEO John Lechleiter http://www.clipsyndicate.com/video/playlist/367/651971?cpt=8&wpid=98 Bloomberg there were some questions about your forecast. you want to clarify that your guidance is still the same for this year. > our full year, dense, which we gave at the beginning of the year of $3.85-$4 per share remains in tact. that is after taking into account significant items, such as the ones we hauled out this period. that is the range that oil be tracked by most of the analyst. that is still our guidance and we're on track. to meet its >> the biggest question concerning your company, and part of the reason your stock is down 14% this out on a stack of paper, it would have been as tall as the empire state building. this was quite a complex application. the fda tells us they need more time. they chose to take three months. we are pleased about that. the new action date is september 26. >> there are some expectations -- when the fda does approve it, could they approve it with limited uses? and if they would, how does it impact your strategy for that benefit from the full range of therapy that we believe this drug can offer. >> i also want to talk about your top-selling drug, zyprexa, which will be losing patent protection. a competing drug is coming -- is going generic, as well. do you expect that to affect sales? >> it is available in generic. keep in mind, we will also have a much greater share voice in the marketplace since the brand will no longer be actively promoted. we're doing several things to ensure that we maintain a strong reduces the cost associated with hospitalization by keeping people out of the hospital. we know that many people being treated for schizophrenia cycle through different drugs. even with the availability of a generic drug, we are sure that zyprexa will get its fair share of use. >> when it does come off patent protection, do you expect sales of some of the other drugs that did well this quarter like cymbalta, to be a will to make up the difference? >> cymbalta, cialas -- their products growing at strong, double-digit rates. that growth trajectory will continue through the 2011-2012 period. development, and seven so far this year that are entering clinical testing. we're focused on moving the pipeline forward. >> i spoke with the ceo of pfizer yesterday. you recently partnered with merck and pfizer developing drugs. is that the wave of the future? these big companies will have to get together in order to bring drugs to the market? >> all of us will have to find a fundamentally new ways to operate this business. the announcement that he refers to is a pretty competitive collaboration that we hope will result in new tools and new technology that each of the partner companies can then take and use to speed up their own drug discovery process these. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=651971&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=651971&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:LLY Business,Bloomberg Business News,Legal http://player.clipsyndicate.com/view/367/648895 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/648895?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/21/58/351/11e6a2f8-05cf-4ba4-b0b4-4d9743f6ebe9_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Analysis and Discussion with Joel Sendek of Lazard Capital Management</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/648895?cpt=8&wpid=98 Mon, 21 Jul 2008 19:31:00 +0000 M&A Spotlight: Roche to Buy Rest of Genentech for $43.7 Billion Analysis and Discussion with Joel Sendek of Lazard Capital Management http://www.clipsyndicate.com/video/playlist/367/648895?cpt=8&wpid=98 Bloomberg gentech shares are gaing more than 11% today after roche offer to buy the rest of their shares for $43.7 billion, $89 a share. our next guest expects it genentech to refuse the bid. he is an analyst at lazard capital market and has a buy rating on gentech. thank you for coming on the show. first of all, why does roche have to bite? they only -- they already own 56 they already own 56% of the company. > we were hoping genentech would stay dependent. but it is trading such an attractive asset that it is easy not to make a bid. what are you expecting to play out here? obviously, investors think the shares will go for closer to $100. do think roche comes out and raises the bid? >> they will not do that immediately. they will have to go through a process. what is -- what will happen first is that there is the board of directors of genentech that will either accept or reject the bid. on the basis of that, they will go to the next step. our estimate is we think there's >> i am wondering about the timing of the deal. it does not look like they are at a weak point considering or their shares are trading. what is roche come in here and do it now? > there is a major catalyst coming up which is a steady for the major drug -- a steady about the major drug coming out. it could be what they want to do is get a bid in before the data comes out if they have insight that it will be positive. if they do it after that data, it is possible -- positive, they will get a higher price. >> what if they fail? what is the other option? they have the cash to do something. >> yes, they have cash. they have a pipeline that is not it remains to be seen whether genentech's view is on this. on the basis of covering the stock for 10 years so, my assumption is that genentech would prefer, even with this premium, to retake the economy. >> what if they do not get it? >> the gentech culture is a unique one. it is different from pharma and biotech. when they are not independent, yet to expect some attrition as far as the key people that have driven the pipeline over the 30 years the company has been in existence. >> that would make the deal even more expensive for roche. even if they buy it, they will have to convince scientists and consolidate all of roche's u.s. pharmaceutical business under the genentech and move it from new jersey over to south san francisco which is a considerable shift on the part of roche in an attempt to get this deal done. >> may be a nice move for those people working on the east coast to want a little more fun and sun. thank you so much for joing us. talking about the roche offer for genentech. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=648895&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=648895&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> VTX:ROG, NYSE:DNA News,Business,Science & Technology,Law & Legal Issues,Health,Shopping & Commerce,Personal Finance http://player.clipsyndicate.com/view/367/649334 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/649334?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/22/58/351/1f8ac8aa-bb6e-4cc4-ae39-00c90d49a5c4_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Schering-Plough, Merck's Vyortin fails to cut risk of heart valve diseases; Eisai wins appeal ruling to block generic Aciphex; Analysis by GV Pasad, Dr. Reddy's Laboratories Vice Chairman & CEO </td></tr></table> http://www.clipsyndicate.com/video/playlist/367/649334?cpt=8&wpid=98 Tue, 22 Jul 2008 04:41:00 +0000 US Drugmakers Tumble; Insight, Outlook For Pharmaceutical Sector Schering-Plough, Merck's Vyortin fails to cut risk of heart valve diseases; Eisai wins appeal ruling to block generic Aciphex; Analysis by GV Pasad, Dr. Reddy's Laboratories Vice Chairman & CEO http://www.clipsyndicate.com/video/playlist/367/649334?cpt=8&wpid=98 Bloomberg one cholesterol drug failed to study everything -- they are down by 11%, merck is down by 6%. this was connected to a higher rate of cancer. the revenue from these companies -- they are looking at a joint venture. there is a u.s. court ruling blocking the drug -- the court of appeals is forcing the japanese companies for taking these challenges. drugs -- this will expire in may of 2013. they generated $1.6 billion in global sales. a very good day, thank you for joing us. what would you do here right now? >> we have not finalized a strategy just yet. we are looking at the weaknesses -- this is a non infringement -- this is part of the business -- we are trying to get affordable medicine. >> is this going to be lost -- what do you believe that there will be an appeal. >> we have not made up our mind -- >> is this going to be affecting your profit outlook? >> we do not usually involve these. >> this was in line with analysts' estimates. these sales actually rose -- the question is, can you translate this into more profit? >> i believe that i am confident that we can. this will normalize what will happen in the coming quarter. we are launching this -- and we may see increased profitability. >> what kind of increased profits are you looking at right now? >> we are looking at the volatility right now. we will be increasing the profit in the long term. >> the u.s. sales rose 53%. do you have any other major market movements that you will see to keep the sales growing. >> of parts from germany and the > what about the weakness of the indian rupee against the dollar? what are you doing, are you hedging against the indian rupee? >> we have a little bit more exposure -- and we have a lot of this based on the imports, one- third of these we have left open. > thank you very much for joing us today. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=649334&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=649334&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:MRK, NYSE:SGP, TYO:4523, BOM:500124 News,Business,Bloomberg Business News,Pharma http://player.clipsyndicate.com/view/367/647253 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/647253?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/18/58/351/caad32be-a5f0-4d48-9b7f-5134537b598f_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Joint Interview with Teva CEO Shlomo Yanai and Barr CEO Bruce Downey</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/647253?cpt=8&wpid=98 Fri, 18 Jul 2008 17:38:00 +0000 Inside Look: Teva Buying Barr (Part 1) Joint Interview with Teva CEO Shlomo Yanai and Barr CEO Bruce Downey http://www.clipsyndicate.com/video/playlist/367/647253?cpt=8&wpid=98 Bloomberg the world's biggest maker of generic drugs, teva pharmaceuticals, agreed today to purchase barr pharmaceuticals, priced at $7.5 billion. joing us, both c.e.o.'s and the studio. welcome, gentlemen. glad to have you. it is unusual to have you acquire a stock on the day and acquisition is announced. is wall street happy with the premium that you paid? do you think the cash and stock combination made sense to investors? >> i think investors see this acquisition, and i think it is also a very compelling economically. > standard and poor's reaffirmed its aaa + rating on the company today. they say if you do in fact have your debt remaining more than a year, maybe they will revisit that rating. is that something of great concern or not? >> i think we have the cash flow and we're smart about it. within the fourth quarter of closing, we are ok. >> you said the timing was right of the purchase. why now? >> i think the strategic fit was very compelling, more so than in the past. this was the 12th serious attempt to acquire barr pharmaceuticals since i've been here, and none of the other 11 have seemed bright. this one was a strategic fit, particularly where we are in the business. generics are coming into the fore, the complementary nature of the eastern europe business, the u.s. business, or brand business fits with theirs. it was a compelling story, and i think that is what wall street is responding to. >> it is the geography counting more or the product lines? >> i think all of the factors. the real key to the reaction and teva's share price, it is widely recognized we have the two strongest companies in the industry and the combination creates separation between teva and the rest of the pack. i think people recognize that. >> you have a lot of competition in this generic field. >> that is true, but we believe that we can grow the business and get stronger and it is part of what we should do in this environment. >> we discussed this morning both the synergies that we expect from this transaction, but we also mentioned there is a big opportunity for us. teva has a growth strategy aimed to double the business. >> by 2012? > by 2012, 20/20 vision as we call it. we aim to double down on the product portfolios, getting the products, knowing how people will get that. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=647253&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=647253&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NASDAQ:TEVA, NYSE:BRL News,Business,Science & Technology,Law & Legal Issues,Health,Shopping & Commerce,Personal Finance http://player.clipsyndicate.com/view/367/647021 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/647021?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/18/58/351/7b123425-2fff-431b-8511-d5e1f2667d92_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Analysis and Discussion with Jeffrey Kraws of Crystal Research Associates</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/647021?cpt=8&wpid=98 Fri, 18 Jul 2008 13:48:00 +0000 M&A Spotlight: TEVA Buying Barr for $7.46 Billion Analysis and Discussion with Jeffrey Kraws of Crystal Research Associates http://www.clipsyndicate.com/video/playlist/367/647021?cpt=8&wpid=98 Bloomberg > welcome back to 'starting bell.' markets now are lower across the board. the dow continues to move around, the s&p and nasdaq are trading under water. a pretty big beating today. we have been talking all day long about the merger and acquisition deal. today a deal was announced to buy a bar pharmaceuticalsr. -- a deal to buy barr all the deals are at a 42% premium, an excellent deal that gives them double revenue. they should experience cost savings of three entered million dollars a year in three years, and this will make and the largest generic manufacturer in the u.s.. >> some have said there is not that much out there anymore. >> we recently saw acquisitions. we will continue to seek consolidations as they worked to improve synergies as well as gain market share. this deal gives 816% market share. 70 billion in generics going off by 2012, 67% of prescriptions enable delivery methods that will be interesting to pharmaceutical companies. the biggest risk in all this is that the companies come together and it does not work or that this company experiences significant competion for the drugs ahead of time. i believe that bruce dowry was the best ceo, this is an excellent deal for shareholders, and this will give them significant execution potential. >> even at this price, you would be buying into these companies? >> i would be buying into the generics, certainly. the generic industry should experience 6-12% growth at least. year. watching the markets and talking to a trader about what he is watching today. stay with us. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=647021&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=647021&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NASDAQ:TEVA, NYSE:BRL Business,Bloomberg Business News,Pharma http://player.clipsyndicate.com/view/367/640104 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/640104?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/9/58/351/14fc3ced-e68a-4bf3-9536-daeb5b4900c9_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Analysis and Discussion with Alexander Young of S&P</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/640104?cpt=8&wpid=98 Wed, 09 Jul 2008 16:13:00 +0000 In-Depth Look: The Health of Health Care Stocks Analysis and Discussion with Alexander Young of S&P http://www.clipsyndicate.com/video/playlist/367/640104?cpt=8&wpid=98 Bloomberg during past slowdowns investors often steer themselves toward health care, the argument being people will get sick and need care and medicine a matter how good or bad the economy is. in this slow down, it is different. the s&p 500 health care index has 12 -- slipped 12% so far this year. some say that makes them a good buy now. the forward price-to-earnings ratio has fallen from above 17 times earnings down to 13.7. that is a little below the forward p/e ratio for the s&p 500, which is about 14. standard and poor's equity research team is just one to operate health-care stocks to market perform from underperform. the index rose almost 3 percent today. it is still climbing. does it mean it is now the right time to invest? >> for his answer we bring in alexander young, equity market strategist at. imports. >> nice to be here. > why now? why do you think the health care group will outperform? a lot of people have been waiting for that for a long time and have been disappointed. >> we are not looking for out performance, but market performance. we had been under way up until monday, that is will we made the change, not yesterday. we got a little bit more positive because we think a lot of the challenges with thin pipelines and patent expiration and generic competion, electoral uncertainty, all of those negatives are still there but the call is on valuation. under 14 times, a discount to the market. we think a lot of the negatives are priced in and maybe we will see a little more defensiveness that people are expecting in this type of environment. relative to what you can expect in terms of earnings and irrelevant -- revenue predictability and other sectors like consumer discretionary and financials, we think health care still holds up pretty well especially given how much prices have come down. that is why we went to a longstanding negative view to neutral on monday. >> what we are showing on the screen is a broad index, an awful lot of different stocks. there have been some success stories. biotech firms -- celgene, for example -- that have been outperforming. >> it is about delivering strong sales growth, and the do not want to be incumbent -- affected by patents expire res -- expirings. we wonder how stable this is, as the companies get more mainstream and regulatory attention, a lot charge a lot of money for products with the significantly lower efficacy than what you might see from a cholesterol drug in a big pharmaceutical company. we are still neutral on biotech. the outsourcing of clinical trial work is exciting. it plays to the pricing constraints in the industry. the symbol cvd is a stock that has been doing well, it helps pharmaceutical companies make more money by more efficiently handling a lot of their early stage trial work. that is an area we will be looking at. > i want to take a look at this. viewers can see it on the screen. it is an expensive stock when you take a look at some of the competive -- competitors. life science, quest request is and blow -- quest is in blue. is it worth the money? >> p/e ratio is a reflection of the street confidence -- confidence in the stock. you cannot look at p/e ratio in a vacuum. a big one is not necessarily bad if there is growth to back up. if you look at earnings per share year-over-year, in both names you will see a huge gap that we think justifies the higher the valuation. > hmos? >> as we go to an election where more and more people are forming a consensus that things have to be done regarding health care costs, there is talk about medical reimbursement rates and a key programs like medicare and medicaid. so, this is really a big issue for a lot of the managed care companies. the government by far right's the biggest checks to the companies, so any changes in those reimbursement rates can have a big impact. you are also seeing slower premium growth, a lot of competition. a lot of the low hanging fruit from medicare part d has been harvested, so it is a much tougher environment over all. >> if a democratic administration is there and there is a push toward universal health care, you would put a sell on a hmo companies? >> that would be of to our analysts, but certainly at a -- that would be up to our analysts, but as a strategist it would not be well for the sector but at this point we did not see it happen. >> when you say health care, a lot of people think of big pharmaceutical companies. king pharmaceuticals and others do it well, but the real big ones are doing poorly. will it change? >> on valuation they have probably fallen enough. but none of the fundamental headwinds have gone away. a drug like lipitor, a fifth of pfizer's business going away in a couple of years and they did not have anything that can come close to replacing that. it is a major challenge not going away. i think the valuation and yield puts a floor under the stock, so we have a hold on it. but pfizer is not out of the woods. you need to see the meaningful pipeline issues addressed to get the stuff going on the upside. >> not a particularly convincing argument for someone looking for a defensive play if the company has to go and grow by acquisition and not organically like pfizer, which for some, is a one trick pony. >> especially when there is so much revenue to replace. acquisition is great when you can move the needle. if you lose patent exclusivity on a quarter of your business, you have to do a lot of deals to offset that, and there have already been a ton of deals years ago. who is pfizer going to buy? the deals tend to be tucked in, they are nice but they will not offset lipitor. >> we thank you for joining us as always. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=640104&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=640104&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:CVD, NYSE:WYE, NYSE:PFE News,Business,Science & Technology,Law & Legal Issues,Health,Shopping & Commerce,Personal Finance,Government & Politics http://player.clipsyndicate.com/view/367/640131 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/640131?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/9/58/351/dbbb6f72-a93e-4849-b156-eff75a98245a_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">How Do You Know the Products You're Using are Safe?</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/640131?cpt=8&wpid=98 Wed, 09 Jul 2008 16:47:00 +0000 Today in Washington: Import Safety How Do You Know the Products You're Using are Safe? http://www.clipsyndicate.com/video/playlist/367/640131?cpt=8&wpid=98 Bloomberg we are focused on health care stocks this hour, and one issue facing them, import safety. right now in with you -- if you take a drug, in a salad, buy toys, how you know they're safe? we do not always know. it is a problem for the government and industry. lindsey arent has the details. the last year the u.s. imported two trillion -- >> last year the u.s. imported two trillion dollars worth of products coming through 3000 ports of entry. it makes a pretty tough to ensure the safety of products. that number is also expected to rise as international trade multiplies, and analysts say it's simply exposes the need for fundamental changes to the import system. that was the topic of a conference intent -- attended today where government and industry trying to collaborate on the verification, tracking, and prevention when it comes to import safety. >> in the next 12 months to 24 months, something far more significant than the olympic gold medals are at stake. it is the future of product safety in the united states. it is going to be redefined. >> officials announced a pilot program where the u.s. will collaborate with the eu and australia on inspections of overseas drug makers and they will share their findings as a way to check. as you know, at least 80 percent of the active ingredient -- ingredients by u.s. drug makers are imported and lawmakers have complained the fda is not doing enough overseas inspections to ensure the safety of these foods and medications. the fda tells bloomberg cannot do all the legwork of import safe by itself, but business needs to step up. > industries that are producing and developing these products have to be responsible for the quality of those products. and taking steps to build that quality in, and quite frankly, protecting brand equity in that investment so they are able to deliver products of quality to consumers or to patients. >> the announcement comes at a time when consumers and food companies are still reeling from the recent salmonella outbreak traced to tomatoes. that alone cost that industry nearly $100 million. business leaders are voicing concern about how tight regulations might affect the bottom line. >> every state will potentially want their own imprint on how they are standing up for safety for the consumer. that is great in principle, but it does not really reflect the reality of the business world. >> one solution being discussed to help the fda and businesses shoulder the burden of the food and drug inspections is to basically help establish a better role for the private sector to play in traing and employing third-party auditors who can inspect manufacturing plants and farms overseas. > thank you very much. lindsey arent from d.c. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=640131&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=640131&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Business,Law & Legal Issues,Shopping & Commerce,Personal Finance,Government & Politics http://player.clipsyndicate.com/view/367/637840 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/637840?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/7/7/58/351/5770cf3d-58a8-48c2-8a10-02cf73a0d90e_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Analysis by David Darst of Morgan Stanley Global Wealth Management</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/637840?cpt=8&wpid=98 Mon, 07 Jul 2008 10:17:00 +0000 Insight, Outlook For Pharmaceutical Sector; Finding Value In A Bear Market Analysis by David Darst of Morgan Stanley Global Wealth Management http://www.clipsyndicate.com/video/playlist/367/637840?cpt=8&wpid=98 Bloomberg let's get back to david darst from morgan stanley global wealth management. you mentioned that you like healthcare. something i read over the weekend, they are saying in the early stages of a decline from the peak down 20% bear. the traditional read oout said they head up relatively well but after the bear market is official at minus 20% the two do slightly worse. so that it me would say if we are two-thirds of the way through the bear market healthcare is the last place i want to be. >> that is the traditional way. this time the healthcare hasn't done well, carol. you know because of the two p's. politics and surprising/patents. -- pricing/patents. the patents will be rolling off, competition from german networks. condition generics. >> those are fair and signature concerns. >> we say diversification. you look at novartis, up 4%. johnson & johnson down only 2% with the market down 14%. so some of these great companies, if you choose with some judiciousness and diversification they have hung in there. another name that we like on our recommended list is tiva pharmaceuticals. it is giving you exposure to the generics. i think the baby boomers, want ing agonize life -- wanting a nice lifestyle but people are worried about the congress, administration change next year. what will that do for drug pricing. >> what do you think it will do? there was talk going in election but times it takes a while to play out. >> morgan stanley's view is when a democrat comes in you want to be with your generics and focus on them and medical supplies. if a republican comes in, stay with big pharma. it is not as cut and dried as that, but that is the essence of the thrust for the health care sector right now. >> we will take another break and talk more. we are talking with david darst from morgan stanley global wealth management. i know he has one pick for us, i believe it is in the energy <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=637840&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=637840&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Business http://player.clipsyndicate.com/view/367/618787 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/618787?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/6/10/58/351/b832c12a-9aa4-4ee3-a101-f0987fe6dbf1_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Seizures of Fake Prescription Drugs Jumped More than 1500 in 2007, 25% More from 2006</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/618787?cpt=8&wpid=98 Tue, 10 Jun 2008 14:48:00 +0000 Preview: Counterfeit Drugs on the Rise Seizures of Fake Prescription Drugs Jumped More than 1500 in 2007, 25% More from 2006 http://www.clipsyndicate.com/video/playlist/367/618787?cpt=8&wpid=98 Bloomberg the bloomberg investigation shows counted medicines are on the rise around the world. seizures of a prescription drugs jump last year to more than 1500 incidents, nearly 25 percent more than in 2006. the value -- $3 billion, according to the pharmaceuticals securities institute, funded by 26 drug makers. the government and industry data show, the that are selling 19 of the world's 25 biggest selling drugs. all told, seizures in 99 countries last year turned up counterfeits of 403 different prescriptions, even when customs and border protection officers detect, but drugs and turn them over to that you as a -- fda, the fda does not destroy the drug. some members of congress say that is a problem. >> if an american is getting a shipment of viagra or lipitor that is fate, you are saying the fda cannot destroy that? >> that is correct. the fda does not destroy it. it becomes unable to the counterfeiters. i bet in five years this will be a hundred billion dollar criminal enterprise. >> be sure to watch his full report on counterfeit drugs tonight at 6:30 p.m. on bloomberg. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=618787&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=618787&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Business,Law & Legal Issues,Health,Shopping & Commerce,Government & Politics http://player.clipsyndicate.com/view/367/603312 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/603312?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/5/20/58/351/f9a934f1-7f9b-4bb5-8503-0a4e31959a7d_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Ernst & Young Sees $67 Billion in Expiring Drug Patents in Five Years</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/603312?cpt=8&wpid=98 Tue, 20 May 2008 17:38:00 +0000 AstraZeneca and Bristol-Myers Squibb Helping Drug Purchases Reach Record Ernst & Young Sees $67 Billion in Expiring Drug Patents in Five Years http://www.clipsyndicate.com/video/playlist/367/603312?cpt=8&wpid=98 Bloomberg biotech cquisitions and licensing eals hit a ecord 27 million last year. e drug makers are oosting investments he industry. ta nazareth joins s with more on the story. s a or hem cope ith xpiring atents, hey ave ore xpiring icenses hat they can replace. stimated 67 billion rug atents are xpir he ext four-five ears, both companies are trying o find ays to make or the otential loss revenues. eeing fforts round cost ontainment, restructuring f r&d perations egin to einvigorate he internal &d engine. re eeing them reach ut buy attack in he form &a transactions. pencer apital ransactions and -- enture apital ransactions it an all-time high ast ear, iotech nvestments aised 0 billion oans, ost since 2000. ndustry' nitial tock sales ose 1% last ear et to ontinue into this ear he ipo market eing it he credit crunch. rivers or those transactions have not hanged, despite what s going public equity markets. re really riven he strategic needs he igger players in the ndustries, car ompanies and biotech. lobal biotech evenues -- ormer ompanies and biotech. armer mpanies and biotech. hank ou so much. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=603312&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=603312&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:AZN, NYSE:BMY Business,Bloomberg Business News,Pharma http://player.clipsyndicate.com/view/367/611070 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/611070?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/5/30/58/351/848e7ff9-f692-4185-a6f8-9530f20a2f43_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Tainted Drug Imports Set Off Warnings that the FDA Failed to Heed</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/611070?cpt=8&wpid=98 Fri, 30 May 2008 13:19:00 +0000 FDA Missed the Wake-Up Calls on Tainted Imported Drugs Tainted Drug Imports Set Off Warnings that the FDA Failed to Heed http://www.clipsyndicate.com/video/playlist/367/611070?cpt=8&wpid=98 Bloomberg a very important story, exclusive and to the -- investigation long removes learn long before deadly contaminated including its -- ingredients were found in heparin other cases but some of multiple warnings but no actions. documents show fda staffers repeatedly sounded the ala over the safety of drug imports starting way back in 1988. that is when a generic epilepsy drug was recalled after two deaths. yet former fda employees told the bloomberg the agency did nothing to improve safety even as the volume of imports soared. >> the fda has been in a daring work spiral for several years now. with the downward spiral. safety being the major of this is. >> to cut costs companies have turned to a grievance from china and other countries with lower labor costs. 80 percent of the ingredients come from abroad. >> we have had a dramatic shift in where the ingredients, from, and now they're coming primarily from overseas. and that means the fda ability to inspect all of these facilities has been greatly diminished because they just cannot possibly. >> back in 1996 a memo from fda forensic chemistry center worry about imported drugs. 'we have just scratched the surface of the problem of, but drugs and need considerable assistance given the problem under control.' just this month at the officials told congress the heparin deaths or a week of col. the fda for a first from will permanently station about one dozen employees in china. an interesting story. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=611070&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=611070&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Business,Bloomberg Business News,Government & Politics,Public Health,Emergencies & Disasters,Home & Lifestyle,safety http://player.clipsyndicate.com/view/367/612576 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/612576?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/6/2/58/351/ad695f00-cf73-4ed7-9354-58836ba4e9ef_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Interview with CEO John Johnson</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/612576?cpt=8&wpid=98 Mon, 02 Jun 2008 12:14:00 +0000 Spotlight: ImClone Interview with CEO John Johnson http://www.clipsyndicate.com/video/playlist/367/612576?cpt=8&wpid=98 Bloomberg whether or not imclone systems drug works, it does not help patients with a gene mutation found in 40% of colorectal tumors. adding this drove to chemo therapy cut the risk by 1/3. it may help doctors decide the best treatment. i almost wonder the 2000 people in the u.s. will be diagnosed with colorectal cancer this year. joing us for more on this is is john johnson, ceo of imclone. he joins us from chicago. you in building your highly awaited results on the trial. it does not seem like the sam slam dunk. 40% of colon cancer patients may be lost because this drug does not work on them. are you disappointed by the results? > not at all. i think this weekend was great news for a cancer patients. as dr. lynch pointed out yesterday, there have been over 14 studies of 12,000 patients with a lot of other drugs where no survival benefit was shown. only two drugs have shown a survival benefit when added to chemotherapy. what is important to keep in mind about this data and why so many people were excited, is that with this drug trial, we have a broad spectrum of patients. we have patients that were sick or who had performance data two. today, in the united states, only 18% of lung cancer patients get this biological therapy. that is a terrific market for us. it is good for those patients. >> your stock is now down 6% in the pre-market. well you say it is great, your shareholders are saying, no, it is not. >> any time we have an event like this, there's a lot of volatility going on. for us, the good news and the good news for cancer patients is that they now have another option. they felt very great about it. >> how much in terms of revenue will this ad on? >> we do not provide specific guidance in that area. this is the largest cancel market, the lung cancer market. lung cancer is the number-one killer in terms of all the cancer related deaths. for us, it is a large market and we look forward. to going into. >> some analysts are saying it could add up to $700 million in revenue. is that? ? >> like a said, we do not provide specific guidance, but clearly, this is a large opportunity for us. will we have said publicly is that we expect this to be a major growth driver for us. > you are not giving numbers. your company has been talked about as a possible takeover. targets -- possible takeover targets. >> we do not comment on matters related to that. what i have been drawn in to do at imclone was to grow the company. specifically, grow the cancer drug sales along with merck around the world. we're working on a pipeline. we just announced our target will go into phase 1 clinical trials. >> explain what that is. >> is a product that will be in this class of products. it will go first into breast cancer patients. patients will begin enrolling in that study this summer. it is a phase three trial that we have reached a protocol agreement with the fda. >> you were just talking about your pipeline. obviously, some of the criticism on your company is uri one trick pony right now. what, out of all of those, the thing will be your next blockbuster drug? > we love all of the children in our pipelines. the three that are closest are 1121, r2, 11fa. and a 12. it's a nice, exciting target right now. we have about 20 face two troth well be on without product by the end of the year. > those are all cancer related? >> yes. >> how much will you be boosting your research and development spending? >> this year we have given guidance that will increase that by about 20-30%. we're not giving guidance of next year, we're clearly making significant investments in. the. >> where do you see growth for your company overseas? > gross and the u.s. will continue to come from the colon market. we're hoping for fda approval. tremendous on that need. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=612576&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=612576&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NASDAQ:IMCL News,Business,Science & Technology,Law & Legal Issues,Health,Shopping & Commerce,Personal Finance,Government & Politics http://player.clipsyndicate.com/view/367/612979 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/612979?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/6/2/58/351/35450112-1bec-494e-8259-30d3f65f1dbc_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Interview with CEO Ron Cohen; Acorda's Fampardine Helps MS Patients Walk, Company Seeks FDA Approval by 1Q '09</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/612979?cpt=8&wpid=98 Mon, 02 Jun 2008 20:27:00 +0000 Spotlight: Acorda Therapeutics Interview with CEO Ron Cohen; Acorda's Fampardine Helps MS Patients Walk, Company Seeks FDA Approval by 1Q '09 http://www.clipsyndicate.com/video/playlist/367/612979?cpt=8&wpid=98 Bloomberg there might be some big news for patients with multiple sclerosis, about 2 million people across the world suffer from it. they might have some new options. suzanne o'halloran has details. >> acordas shares jumping over 20%. they said that their fampridine drug was very effective in late stage trials. they are said to head to the fda for approval in the first quarter of 2009. i am now joined by the ceo, congratulations. it is very positive. the biggest questions coming from the wall street community is will this help the business forecast? >> they are down over 400,000 people in the u.s. who live with multiple sclerosis. we are still doing our market research in terms of pricing and how many of those patients might benefit and take the drug. we don't have a specific market figure now but we can tell you those of the numbers of people that might be potentially affected. >> i was wondering when you talk about this, how long will it be until patients can take this? >> what we have done is that we have had two late-stage or phase-three clinical trials both of which showed that the drug had the ability to improve walking ability and that is one of the key issues, they'd lose the ability to walk over time. now that we have those trials we need to file a new drug application with the fda and we plan to do that in the first quarter of 2009. it depends on how long it takes for the fda to approve it and hoping that they will review it favorably and allow us to market it. >> it is given in 95% chance of approval, yowhy not sell yourself to a large drug maker? >> there is no sure thing in drug development but we are very encouraged by the data that we have. my job and the job of my team is to come to work every day and develop novel breakthrough therapies witfor people with terrible afflictions. we have new drugs that we want to get approval for by late 2009 as well. that is really where we are focused building a great innovative biotechnology company that can deliver real value to patients. >> you are operating on a net loss, when can you tell your investors that you will turn a profit? will this help you turn a profit? >> that is something that is going to be determined very much by market size and how fast we have potential. those are things that are ahead of us and things that we are researching. we are researching what the costs will be. what we can say is that we think a very large number of patients are likely or potentially could benefit from this drug if it is approved. we think that ultimately it will take the company to a new place where we can function on our own, be profitable, and develop additional therapies that will help other patients. >> the estimate is about 500 million annually when a drug goes globally, is that a fair estimate? >> i am delighted to be here that but we will do our own work. over time we will develop our own internal estimates. >> what about your sales? do you have the sales force to action the market this drug if and when it gets approved? > we do. we have about 65 professionals who are very experienced salespeople in the pharmaceutical industry. we are selling a drug right now which treats very severe symptoms of diseases like ms and a stroke and spinal cord industry. that sales force, that commercial organization, is now cash flow neutral. we are selling enough of the drug to support the entire commercial organization and free up our capital for the innovative programs that we have. wheat wilwe will need to increase that sells forced to sell the new drug in the u.s.. >> i have wondered about the competition. if there are many people out there with multiple cirrhosis treatments. -- multiple sclerosis treatments. > it is completely different and potentially complementary. the existing drugs slow down the number of new attacks that the immune system amounts on the nervous system in people with multiple sclerosis. this is something that has different. it-it goes to the nerve fibers that have been damaged and it allows them to conduct electrical impulses. it actually restores the ability of those nerve to conduct and we have shown that that results in improved walking ability which is a major issue. there are two different benefits that patients could get. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=612979&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=612979&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NASDAQ:ACOR Business,Bloomberg Business News,Health,Pharma,Alternative Health http://player.clipsyndicate.com/view/367/579964 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/579964?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/4/29/4/3/9329371f-9ed1-47e3-a7e8-dd97fccfd136_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">The widow of a man who died after receiving contaminated heparin told a congressional subcommittee Tuesday 'we have a false sense of security' in a land where people expect to be protected and safe. (April 29)</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/579964?cpt=8&wpid=98 Tue, 29 Apr 2008 19:41:01 +0000 Contaminated Heparin Deaths Remembered The widow of a man who died after receiving contaminated heparin told a congressional subcommittee Tuesday 'we have a false sense of security' in a land where people expect to be protected and safe. (April 29) http://www.clipsyndicate.com/video/playlist/367/579964?cpt=8&wpid=98 Associated Press <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=579964&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=579964&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> heparin-hearing News,Health http://player.clipsyndicate.com/view/367/581026 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/581026?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/4/30/62/404/c4891227-6221-4f29-8638-8205e3df717b_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;"></td></tr></table> http://www.clipsyndicate.com/video/playlist/367/581026?cpt=8&wpid=98 Wed, 30 Apr 2008 00:00:00 +0000 Drug Regulators Claim Heparin Was Contaiminated in China http://www.clipsyndicate.com/video/playlist/367/581026?cpt=8&wpid=98 KTTV FOX 5 Los Angeles <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=581026&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=581026&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News,Local News,Government & Politics,Public Health,Emergencies & Disasters,World News,China http://player.clipsyndicate.com/view/367/579578 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/579578?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/4/29/58/351/0016032c-d77c-4b3d-9160-8248dfdb0dcb_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Merck Plans to Submit More Data to FDA to Prove Effectiveness of Drug</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/579578?cpt=8&wpid=98 Tue, 29 Apr 2008 12:50:00 +0000 Merck's Cholesterol Pill Fails to Win U.S. Approval Merck Plans to Submit More Data to FDA to Prove Effectiveness of Drug http://www.clipsyndicate.com/video/playlist/367/579578?cpt=8&wpid=98 Bloomberg merck' holesterol pell has failed in approval fda egulators and hat causing the tock to all this morning. s less han one week after ecommendations or arketing rom the uropean union. he company plans o back to da to how he effectiveness he drug. da ays hat hey need to do more safety tests. bear stearns nalyst ays the holesterol drug ould ave 600 million in ales f approved. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=579578&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=579578&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> NYSE:BSC, NYSE:MER Business,Health http://player.clipsyndicate.com/view/367/577027 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/577027?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/4/25/125/443/2b8fbc58-6645-4b0c-b66e-96ae781a443b_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE - News), today announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR™ (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/577027?cpt=8&wpid=98 Fri, 25 Apr 2008 13:27:48 +0000 Progenics and Wyeth Announce FDA Has Approved RELISTOR Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX - News) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE - News), today announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR™ (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. http://www.clipsyndicate.com/video/playlist/367/577027?cpt=8&wpid=98 News Broadcast Network <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=577027&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=577027&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Health http://player.clipsyndicate.com/view/367/574141 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/574141?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/4/22/4/3/731f705b-3e7a-4c62-b64d-4a74646b0ce7_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">House members chastised the Food and Drug Administration on Tuesday for not stepping up inspections of foreign drug manufacturers in the wake of a litany of problem with the blood thinner heparin and other products. (April 22)</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/574141?cpt=8&wpid=98 Tue, 22 Apr 2008 18:01:34 +0000 FDA Chief Questioned by Congress About Heparin House members chastised the Food and Drug Administration on Tuesday for not stepping up inspections of foreign drug manufacturers in the wake of a litany of problem with the blood thinner heparin and other products. (April 22) http://www.clipsyndicate.com/video/playlist/367/574141?cpt=8&wpid=98 Associated Press <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=574141&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=574141&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> heparin-congress News,Government & Politics,Public Health http://player.clipsyndicate.com/view/367/479553 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/479553?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2007/12/27/58/351/bc9f4519-3ce0-4095-99e5-dff028deda43_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Drug market sales in China expects to loom at 2010.</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/479553?cpt=8&wpid=98 Thu, 27 Dec 2007 17:12:00 +0000 China's Drug Market Drug market sales in China expects to loom at 2010. http://www.clipsyndicate.com/video/playlist/367/479553?cpt=8&wpid=98 Bloomberg CMBREAKPOINT >> CHINA GETS A LOT OF PRESS FOR ITS ECONOMIC GROWTH AND HOW IT IS QUICKLY BECOMING A WORLD ECONOMIC POWER HOUSE BUT YOU MAY NOT HEAR A LOT ABOUT THE FLIP SIDE, DISEASE. HEPATITIS B, CHINA ACCOUNTS FOR MORE THAN A THIRD OF THE CASES AND OBESITY AFFECTS 90 MILLION. IT ALSO HAS POOR AIR QUALITY AND 350 MILLION SMOKERS, MEANING SURGING RATES IN ASTHMA, CANCER. BUT IT HAS NOT BEEN MATCHED IN THE GROWTH OF WESTERN-STYLE MEDICINE. MANY REMAIN LOYAL TO AGE-OLD TREATMENTS LIKE GINGER ROOT, ACUPUNCTURE. FOR PHARMACEUTICAL COMPANIES IT MEANS A HUGE POTENTIAL. CHINA ACCOUNTS FOR 2 PERCENT OF THE GLOBAL DRUG MARKET CMBREAKPOINT ACCORDING TO A RESEARCH FIRM. CHINA' S POPULATION IS 1.3 BILLION, MORE THAN THE COMBINED POPULATION OF THE U.S. AND EUROPE WHICH ACCOUNT FOR 78% OF WORLD PHARMACEUTICAL SALES. CHINA' S DRUG MARKET HAS MORE THAN TRIPLED SINCE 1997 AND IS EXPECTED TO NEARLY DOUBLE BY 2010. THERE ARE BARRIERS, HOWEVER. TO EXPLAIN THIS IS A HEALTH ANALYST. LET' S START BY ASKING WHY CHINESE CULTURE EMBRACES WESTERN CONSUMER GOODS BUT HAS BEEN TOUGHER ON WESTERN MEDICINE. >> IT HAS BEEN A CHALLENGE FOR MANY REASONS. TRADITIONALLY CHINESE MEDICINE HAS BEEN A STAPLE OF THE CHINESE CULTURE AND THAT HAS INHIBITED THE GROWTH. BUT THAT IS CHANGING. IF YOU LOOK AT THE MOST RECENT DATA WE PROJECT THE PHARMACEUTICAL MARKET FOR WESTERN MEDICINES WILL GROW ABOUT 20% IN 2007. IN FACT, THE THIRD QUARTER DATA CMBREAKPOINT SAYS IT GREW ABOUT 29%. GROWTH IS DEFINITELY TAKING OFF AND WE SEE THAT AS PART OF SOME OF THE FACTORS YOU MENTIONED. O.B.T., ISSUES AROUND DIABETES -- OBESITY. THERE WILL BE 37 MILLION CHINESE BY 20/205 WITH OF DIABETES. IN SMOKING -- BY 2025 47 MILLION CHINESE WITH DIABETES. THE BALANCE IS HOW THE CHINESE SEE THIS. THEY WANT TO BALANCE WHAT THEY TAKE WITH TRADITIONAL MEDICINE WITH A LOT OF THE WESTERN MEDICATIONS. >> WHAT KIND OF INVESTMENTS ARE WESTERN DRUG MAKERS MAKING? ARE THEY DOING ENOUGH TO CHANGE MINDS AND WALLETS? >> THEY CAN' T ADVERTISE ON TV LIKE IN THE U.S. BUT THEY ARE VERY INVOLVED IN A NUMBER OF DIFFERENT THINGS TO TRY TO INCREASE AWARENESS. A LOT OF COMPANIES ARE PARTING WITH THE GOVERNMENT. THE GOVERNMENT HAVE A CLEAR AGENDA CMBREAKPOINT F INCREASING THE DOMESTIC PHARMACEUTICAL COMPANIES OF THE SMART WESTERN COMPANIES ARE WORKING WITH THEM. NOVARTIS HAS SET UP DRUG DISCOVERY AND DEVELOPMENT CENTERS IN CHINA. OTHER COMPANIES ARE BALKING AT LICENSING OUT PRODUCTS IN CHINA TO -- ARE LOOKING AT LICENSING OUT SOME PRODUCTS IN CHINA TO GROW THE DOMESTIC PLAYERS BECAUSE THEY COULD CURRIE FAVOR WITH THE GOVERNMENT. >> I CAN IMAGINE THAT INTELLECTUAL PROPERTY PROTECTION COULD CREATE PROBLEMS. >> OF THE FIRST AND LAST RECENT VIOLATION WITH PFIZER AND VIAGRA AND THAT WAS TWO YEARS, SINCE THEN IT HAS BEEN PRETTY GOOD. IF YOU LOOK AT R&D AREA, THEY ARE LOOKING -- A BIT CAUTIOUS ABOUT THOSE INVESTMENTS. THEY ARE PUTTING ASSETS ON THE GROUND THAT ARE MORE GENERAL IN TERMS OF THE DEVELOPMENT WORK IN THE VERY PROPRIETARY ACTIVITIES ARE STILL CMBREAKPOINT APPENING IN AREAS LIKE THE UNITED STATES AND EUROPE FOR THAT REASON. >> I WOULD THINK COSTS WOULD BE LOWER. >> COSTS ARE SIGNIFICANTLY LOWER. IT DEPENDS ON WHICH STUDY, BUT BETWEEN 30% UP TO 60% LOWER. A LOT OF THE CUTS YOU READ ABOUT, NOVARTIS, BRISTOL-MYERS, THAT THEY HAVE TAKEN, UNDOUBTEDLY THAT WILL CREATE JOBS AND OPPORTUNITIES IN CHINA. >> AS YOU CREATE THE JOBS, THE THE CHINESE HAVE THE EDUCATION AND BACKGROUND TO FILL THEM? >> IF YOU LOOK AT THE NUMBER OF EDUCATED ENGINEERS, SCIENTISTS, CHEMISTS, THE NUMBERS ARE FORMIDABLE. I HAVE ALWAYS BEEN IMPRESSED ABOUT CHINESE SOCIETY AS A WHOLE. THEY ARE VERY SMART PEOPLE. A VERY STRONG PUSH FOR EDUCATION GENERALLY. IF YOU LOOK AT THE NUMBERS AND OPPORTUNITY, YES, THE WORK FORCE WILL BE THERE. >> WHICH COMPANIES ARE SPENDING THE MOST AND WHICH HAVE THE MOST POTENTIALS? >> THE BIG LEADERS IN THE WESTERN SIDE -- ASTRAZENECA, CMBREAKPOINT SSUES WITH GRAFT AND CORRUPTION. ONE ISSUE IS THEY HAVE NOT SEPARATED PRESCRIBING FROM DISPENSING. WHEN THE DRUGS GO TO THE HOSPITAL THE HOSPITAL MAKES A MARKUP. CREATES STRANGE DYNAMICS, PHYSICIANS PRESCRIBING DRUGS MAY NOT -- THAT MAY NOT BE IN THE BEST INTEREST OF THE PATIENT BUT MAKES MONEY FOR THE HOSPITAL. >> HOW QUICKLY WOULD WE BE ABLE TO SEE WESTERN STYLE USE? DO YOU SAY THEY HAVE SUCCEEDED IN PENETRATING THE MARKET? HOW LONG WILL THIS TAKE? >> THE MARKET IS ABOUT $14 BILLION TODAY AND TWO-THIRDS IS DOMESTIC OR GENERIC PLAYERS. TRADITIONALLY OVER THE LAST FEW YEARS, BUT DOMESTIC PLAYERS HAVE BEEN TAKING SHARE, BUT THAT HAS CHANGED AND NOW THE WESTERN PLAYERS ARE STARTING TO TAKE MORE SHARE. I WOULD SUSPECT MAYBE THAT WOULD GO UP TO ONE-HALF OR SOMETHING OVER TIME. BUT WHA CMBREAKPOINT IS MOST LIKELY TO HAPPEN IS DOMESTIC PLAYERS WILL INVEST MORE AND THEY WILL REALIZE RESEARCHED BEST BASED MEDICINE IS THE KEY AND NOT THROUGH COPPING -- RESEARCH- BASED MEDICINE IS THE KEY AND IT IS NOT THROUGH COPYING. BUT THE QUESTION IS WHETHER THE CHINESE GOVERNMENT WILL ENFORCE IT. I THINK THEY WILL WITH THE SPATE OF PRODUCT SAFETY RECALLS. >> HERE IS AN UPDATE ON THE SITUATION IN PAKISTAN. FORMER PRIME MINISTER BENAZIR BHUTTO' S PARTY VICE-CHAIRMAN FAHIM IS SPEAKING TO REPORTERS. HE SAID THE PARTY WILL BE MORNING HER FOR 40 DAYS AND SHE WILL BE BURIED IN HER ANCESTRAL GRAVEYARD. HE WAS SITTING NEXT TO HER IN THE CAR WHEN SHE WAS KILLED. HE CANNOT CONFIRM WHETHER IT WAS BULLETS OR A BOMB THAT KILLED HER. SHE WAS WAVING FROM THE SUN ROOF. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=479553&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=479553&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> News http://player.clipsyndicate.com/view/367/487168 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/487168?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/1/8/58/351/a42e3764-a416-4741-a017-e7f66f157e05_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Amgen's 2007 Profit Beats Previous Forecast, According to CEO; Biogen Idec and PDL BioPharma Enter Licensing Agreement; Sirtris Drug Proves in Trials to Help Diabetics Lower Blood Sugar; Isis Cholesterol Drug Being Licensed by Genzyme</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/487168?cpt=8&wpid=98 Tue, 08 Jan 2008 17:24:00 +0000 Biotech Stocks to Watch: Amgen, Biogen Idec, PDL BioPharma, Sirtris Pharmaceuticals, Isis Pharmaceuticals Amgen's 2007 Profit Beats Previous Forecast, According to CEO; Biogen Idec and PDL BioPharma Enter Licensing Agreement; Sirtris Drug Proves in Trials to Help Diabetics Lower Blood Sugar; Isis Cholesterol Drug Being Licensed by Genzyme http://www.clipsyndicate.com/video/playlist/367/487168?cpt=8&wpid=98 Bloomberg head and an upper level system, will produce the severe weather. maybe another. of rain for chicago. nothing like you saw last night. miami, 80 degrees with some sunshine. now back to you. >> biotechnology stocks are on the move today with the amex biotech index with the second day of gains. brett gering has more. >> a lot going on in this group said. amgen as you said is one of the biggest winners on the amex biotechnology index. in fact, one of the best performers and one of the most heavily traded on the nasdaq stock market today. the ceo presenting at the j.p. morgan health care conference in san francisco. saying the company earned more last year than the company previously forecast. that was on cutting expenses and offset declining sales of the anemia drug. n the other side, by a gen idec and another company entered in the next route -- an exclusive agreement for a company to develop a treatment for macular degeneration in the elderly. it will get an equity position and milestone payments and royalties. monday during -- you may remember there was forecasted revenue gain of 20% this year and the stock gained the most since october on the news but is giving back some today. both biogen and pdl are the worst performers on the index. another pharmaceutical, a drug based on the active ingredient in red wine, helping diabetics lowering its blood sugar. finally, isis pharmaceuticals is oaring higher, the stock and -- at the highest since april 2002. genzyme will license the company' s cholesterol lowering drug and be paid $175 million to start in that partnership. genzyme is also buying 5 million shares for $150 million. in about 10 minutes we will bring you an interview with the ceo of isis pharmaceuticals at about 12:35 p.m. eastern time. >> thanks very much. automakers and suppliers worldwide feeling good of our profitability. a new survey from kpmg shows 26 percent expect profits to rise in the next five years. in 2005 and into insolvent -- 2006, only 16 percent predicted. factors include new labor contract, restructuring including plant closings and layoffs in america, and growth in emerging markets. how <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=487168&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=487168&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Healthcare, Finance News, Public Companies, Technology News http://player.clipsyndicate.com/view/367/487212 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/487212?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2008/1/8/58/351/720ac8b4-de60-4355-9577-0a361e431dff_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Interview with CEO Stanley Crooke</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/487212?cpt=8&wpid=98 Tue, 08 Jan 2008 17:37:00 +0000 Isis Pharameuticals Shares Surge on Genzyme Pact Interview with CEO Stanley Crooke http://www.clipsyndicate.com/video/playlist/367/487212?cpt=8&wpid=98 Bloomberg >> shares of all races pharmaceuticals rising as much as 30% today. -- isis pharmaceuticals. it will buy the -- genzyme will license its cholesterol lowering drug and will uy 5 million shares, which is $150 million. joining us to talk about it is the ceo, stanley crooke. it really glad to have you. tell us more about the product. how is it better than what is the potential market value? >> it is a second-generation -- it is a very selective in his battle -- and her brother. -- inhibit. what makes it unique is that it lowers all lipid and has a linear dose response curve the works the same in every patient who sees -- works in the present cost of a moderate or high doses patents court in the absence equally well. it is a drug that will be used for patients who have high cholesterol who are at high cardiovascular risk and cannot get to the target with other drugs. it also does not have drug/drug interactions or toxicities so it is an ideal drug for patients who have had a heart attack, for example, form to but they are off on 10 or 11 other drugs. >> why did you feel the need to take on a partner? >> our strategy from inception was to invent the technology, created a large group of drugs and licensed the drug prior to beginning of large phase 3 trials. we think our model makes much more sense before a technology as efficient as this. we have been in the process of licensing it for the past six or seven months, and we decided that genzyme was right partner. >> the larger picture, stanley. you found that basis, at least seven the past, because you said big harmaceutical our diet -- dinosaurs that cannot adjust. will biotech lead the way permanently? >> i do think we need to experiment with new technologies, and i think they are poorly managed in large pharmaceuticals, and we have to experiment with new models of the company. the model we have in mind is a very different one from a fully integrated pharmaceutical companies. over time i think we will find solutions that include productivity in both technology and organizational base. >> if that is a case, would you be an attractive target with a big pharmaceutical company? would you sell? >> certainly not at these prices. i think things we doubt about licensing this drug to genzyme, a relationship that certainly does not mean we are being acquired and some ways protect us from an unwanted acquisition. >> you mentioned the connection to genzyme. it gives the country preferred asked -- access to future treatments. what does it mean, the right of first refusal? >> basically on similar types of terms. so, these drugs that we develop them do not cross an intact blood brain barrier so they have to be administered directly into the spinal column so they would be geared to the very severe diseases like alzheimer' s, like als, and genzyme, of course, is an ideal partner to commercialize those drugs as well. a new area that we are excited about. >> you -- thank you very much. >> stock markets in china, india, brazil, turkey all had gains last year. more in 2008? your active investor has a fund with a return of 36%. <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=487212&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=487212&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Finance News, Technology, Healthcare, Public Companies Business http://player.clipsyndicate.com/view/367/466440 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/466440?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2007/12/10/58/351/c1674749-4c63-4c1c-822b-9e4ea0c137b8_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Merck May Lose to Doctors Keeping Cholesterol Pills Off Shelves</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/466440?cpt=8&wpid=98 Mon, 10 Dec 2007 15:40:00 +0000 In-Depth Look: Scrutiny Over Merck's Cholestrol Drug Merck May Lose to Doctors Keeping Cholesterol Pills Off Shelves http://www.clipsyndicate.com/video/playlist/367/466440?cpt=8&wpid=98 Bloomberg CMBREAKPOINT >> ALMOST 90 MINUTES INTO THE TRADING DAY, AND THE DOW, S&P AND THE NAVTEQ REMAIN HIGHER AND NEAR THE HIGHS OF THE SESSION. THE DOW IS UP 100, THE S&P GAINING A 11, AND IT IS FINANCIALS, MATERIALS, AND ENERGY STOCKS HELPING LEAD THE S&P. IN TERMS OF THE NASDAQ, WE ARE UP ALMOST 16 ON THE NASDAQ. LET US START WITH THE TREASURY MARKET, BECAUSE WE ARE SEEING TREASURY PRICES DROPPING, DOWN 15/32 ON THE 10-YEAR, THE YIELD AT 4.17%. WE DID GET THE PENDING HOME SALES MORE THAN ECONOMISTS HAD EXPECTED, AND YOU CAN SEE THE TWO-YEAR NOTE IS DOWN 1/32, THE YIELD AT 3.12%. WELL, CMBREAKPOINT ERCK WAS THE FDA TO LET IT SELL ITS CHOLESTEROL MEDICINE OVER-THE-COUNTER BUT THAT MAY CAUSE THE DRUGMAKER SOME PROBLEMS WITH DOCTORS. JOINING US NOW IS OUR REPORTER COVERING THE STORY FOR US TODAY. SHANNON, LET US GET YOUR SENSE OF WHY MERCK WANTS TO DO THIS AND WHY DOCTORS ARE OPPOSED? >> THESE CHOLESTEROL DRUGS ARE THE MOST PRESCRIBED IN AMERICA. THEY HAVE $16 BILLION IN SALES AND THE U. S., AT VERY POPULAR DRUGS. MERCK WANTS TO SELL ONE OF ITS OLDER DRUGS WITHOUT A PRESCRIPTION. DOCTORS SAY THEY DO NOT THINK PATIENTS CAN SAFELY TAKE THEM AND PROBABLY TAKE THEM WITHOUT A DOCTOR' S SUPERVISION, WITHOUT SOMEONE DIAGNOSING THEIR HIGH CHOLESTEROL, WITHOUT SOMEONE TELLING THEM WHAT IT HAS GOTTEN LOW ONE OF. AND ALSO WITHOUT SOMEONE BEING ABLE TO MONITOR FOR SIDE EFFECTS EVEN THOUGH THE DRUGS ARE RELATIVELY SAFE. >> WHY DOES MERCK THINK THE SELDOM OVER THE COUNTER? >> THE COMPANY THINKS THERE ARE A LOT OF CMBREAKPOINT MERICANS, 14 MILLION, WHO ARE NOT TAKING A CHOLESTEROL DRUG BUT THE BENEFIT. THEY ARE SAY MORE WOULD BE LIKELY TO TAKE ONE IF IT IS OVER THE COUNTER, IF THEY WOULD NOT HAVE TO COME IN FOR A PRESCRIPTION REFILL. >> WHAT ABOUT THE FDA? WOULD LIKELY BE PASSED? >> ANALYSTS ARE NOT EXPECTING IT TO BE APPROVED BY THE FDA. MERCK TRIED THIS IN 2000, IN 2005, ABOUT TIME THE FDA SAID THEY DID NOT THINK PATIENTS COULD APPROPRIATELY TAKE. THEY WERE CONCERNED PEOPLE WHO DID NOT NEED THE DRUG WOULD TAKE IT BECAUSE THEY WERE CONCERNED ABOUT IT BECAUSE THEY WERE OVERWEIGHT OR CONCERN THAT PATIENTS WOULD TAKE IT AND THEN NOT GO TO GET CHECKED OUT TO SEA OF THE CHOLESTEROL GOT LOWER. >> TALK ABOUT THE STANDARDS. BEHALF OF THE STANDARD DRUGS MUST ME TO BE SOLD OVER THE COUNTER. >> OF COURSE, IT HAS TO BE PROVED THAT IT IS SAFE AND EFFECTIVE. THEY ALSO -- THEY ARE DRUGS WHERE PEOPLE CAN SELF DIAGNOSED LIKE A HEADACHE. CMBREAKPOINT IT IS EASY TO TELL IF YOU HAVE A HEADACHE. BUT FOR CHOLESTEROL YOU NEED TO GO TO A DOCTOR OR CLINIC. >> NOW, AS WELL, MERCK HOLDING AN ANALYST DAY TOMORROW. WHAT SHOULD INVESTORS EXPECT? >> THEY WILL BE UPDATING EVERYONE ON THE PIPELINE. THERE ARE A FEW COMPOUNDS THAT EVERYONE IS WATCHING -- ONE FOR OBESITY, AN APPETITE SUPPRESSANT, AND ONE THAT WOULD RAISE GOOD CHOLESTEROL TO HELP LOWER ARTERY CLOGGING THAT CHOLESTEROL. THOSE ARE TWO PEOPLE WILL BE WATCHING CLOSELY TO SEE IF THE FDA WILL MOVE THOSE INTO THE NEXT STAGES TO GET APPROVAL. >> THANKS SOMEWHAT, FOLLOWING MERCK STORY, AND OF COURSE SHE WILL FOLLOW THE ANALYST MEETING TOMORROW. FINALLY, THE ONLY MAJOR NEW MOVIE THIS WEEK AND GRABBED THE TOP SPOT AT THE BOX OFFICE, THE FANTASY FILM "THE GOLD AND COMPASS -- GOLDEN COMPASS <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=466440&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=466440&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Finance News, Healthcare, Public Companies, Government News http://player.clipsyndicate.com/view/367/466632 <table border="0" cellpadding="0" cellspacing="0"><tr valign="top"><td><a href="http://www.clipsyndicate.com/video/playlist/367/466632?cpt=8&wpid=98"><img src="http://video-static.clipsyndicate.com/cs-video/vol2/2007/12/10/58/351/0d058e38-07e5-4906-a98d-3177e2186456_120x90.jpg" width="120" height="90" border="0" /></a></td><td style="padding:5px;">Interview with CEO Deborah Dunsire</td></tr></table> http://www.clipsyndicate.com/video/playlist/367/466632?cpt=8&wpid=98 Mon, 10 Dec 2007 18:25:00 +0000 Millenium Pharmaceuticals Shares Up After Drug Spurs Remission in Multiple Myeloma Interview with CEO Deborah Dunsire http://www.clipsyndicate.com/video/playlist/367/466632?cpt=8&wpid=98 Bloomberg CMBREAKPOINT M MICHAEL MCKEE. >> WE' RE GOING TO SHOW YOU HOW THE MARKETS ARE MOVING. DOW JONES, S&P 500 AND NASDAQ ARE ALL CLEARLY HIGHER, JUST ABOVE INTRADAY HIGHS. WE WILL SHOW YOU THE 10-YEAR NOTE IS DOING, ONE DAY BEFORE THE FED DECISION. THERE YOU HAVE IT. DOWN 10/32, YIELD AT 4.14%. >> SHARES OF MILLENNIUM ARE JUMPING. ABOUT 9% HIGHER. VELCADE STOPPED THE CANCER FROM BEING ACTIVE IN 1/3 OF NEW PATIENTS. SHARES OF THE RIVAL ARE FALLING ON THE NEWS. 35% OF THOSE THAT TOOK VELCADE HAD A COMPLETE REMISSION, COMPARED WITH 5% OF RON IMMUNE DRUGS ALONE. IN A BLUEBERRY IS LISTEN, WE' JOINED BY DEBORAH DUNSIRE, PRESIDENT AND CEO OF MILLENNIUM PHARMACEUTICALS -- IN A BLOOMBERG EXCLUSIVE. SHE COMES TO US FROM ATLANTA. DOES THIS CHANGE THE COMPETITIVENESS BETWEEN YOUR DRUG AND A COMPETITOR? >> VELCADE HAS BEEN MOVING INTO THE FRON CMBREAKPOINT INES. NOW WE' RE SEEING THE SAME THING IN THE FRONT LINE SETTING. THIS IS GREAT NEWS FOR PATIENTS. I THINK WE HAVE THREE VELCADE STAGE THREE TRIALS THREE PRESENTED AT THIS MEETING IN THE FRONT LINE SOMETHING. WE SEE THAT VELCADE CAN BE COMBINED WITH A WIDE VARIETY OF AGENTS. I THINK AS OTHER COMPETITORS, TO THE MARKET, WE WILL SEE THE RIGHT COMBINATION COME TOGETHER FOR MYELOMA PATIENTS. AS YOU KNOW, YOUR BEST SHOT AT CURING CANCER IS GETTING IT EARLY. THAT IS WHAT THE DATA WITH VELCADE AND THE FRONT LINE SETTINGS SHOW. IT IS SO IMPORTANT. >> WAS THE MOST MEANINGFUL, PRECISE DATA THAT YOU SAW YESTERDAY? IT WAS -- WAS THE MOST MEANINGFUL DATA? >> THERE WERE TWO TRIALS, ONE IN TITIAN' S NOT ELIGIBLE FOR TRANSPLANTS, WHICH IS THE MAJORITY OF MELANOMA PATIENTS. -- ONE IS IN THE MAJORITY OF PERRY CMBREAKPOINT ATIENTS NOT ELIGIBLE FOR TRANSPLANTS. THEN WE SAW VELCADE INCREASE OUR MISSION IN 35% OF PATIENTS. COMPLETE REMISSION THE -- THE ABSENCE OF THE DISEASE. THAT IS A VERY GOOD SURROGATE AND PREDICTOR. OVERALL, EVEN THOUGH THE FOLLOW- UP IS RELATIVELY SHORT. WE HAVE NOT FOLLOWED THIS FOR YEARS AND YEARS. EVEN WITH A MEDIUM OF A 16 MONTH FOLLOW-UP, THERE ARE THE STATISTICAL SIGNIFICANT DIFFERENCE BETWEEN THE VELCADE AND THE ARMED NOT CONTAINING VELCADE. THIS AGENT CAN GIVE THEM A BETTER SHOT AT SURVIVAL. CUESTAS AS A CHANGE PETRAEUS STANDARDS? -- >> DOES THIS CHANGE TREATMENT STANDARDS? >> THIS BRINGS A WHOLE NEW OPTION FOR WORD. IN ADDITION TO VELCADE THE TRIAL TO -- IN ADDITION TO THE VELCADE TRIAL, WE ALSO SAW IT PREVENTED CMBREAKPOINT N ANOTHER TEST. IT SHOWED OUTSTANDING COMPLETE REMISSION RATE. -- IT SHOWED OUTSTANDING COMPLETELY PERMISSION RATES BEFORE A BONE MARROW TRANSPLANT AND THEN AFTER A BONE MARROW TRANSPLANT. WE HAVE SEEN THAT VELCADE COMBINED WITH VERY DIFFERENT THERAPIES TAKES EACH OF THOSE TO A NEW LEVEL. THAT' S WHY I THINK THIS DATA IS SO IMPORTANT WHEN NEWLY DIAGNOSED MELANOMA PATIENTS. NO MATTER WHAT THE THERAPY THEY HAVE BEEN ON, VELCADE CAN TAKE IT TO A NEW LEVEL AND POTENTIALLY OFFER THEM A BETTER SHOT AT A CURE FOR LONG-TERM SURVIVAL OF -- OR LONG-TERM SURVIVAL. >> WHEN YOU EXPECT TO GET A APPROVAL FOR THIS? >> OF FALLS AT MILLENNIUM ARE WORKING VERY HARD TO INSURE THAT WE CAN SUBMIT THE PROPER DRUG BY THE END OF THIS YEAR. -- OUR FOLKS AT MILLENNIUM ARE WORKING VERY HARD. THIS TRIAL WAS ONLY STARTED IN SEPTEMBER. CMBREAKPOINT ITHOUT THE FDA, FULL PRIORITY REVIEW, IS UP TO THE FDA WHETHER THIS DATA WILL BE AFFORDED THAT PRIORITY REVIEW. WE CANNOT GUARANTEE IT. DURING 2008, WE WILL HAVE AN APPROVAL IN THE FRONT LINE SETTING. >> WE TALKED ABOUT WHAT THIS WOULD DO FOR PATIENTS. WHAT DOES IT DO FOR MILLENNIUM? AND ANALYSTS YESTERDAY SAID THE STUDY' S FINDINGS HAD BEEN ANTICIPATED, YET THE STOCK IS SOARING ANYWAY. PEOPLE THINK YOU' LL MAKE A LOT OF MONEY. >> IN BROAD AS THE POPULATION OF MYLAN AMONG PATIENTS. WE HAVE SEEN -- IT PROMOTES THE MAJORITY OF THE MELANOMA PATIENTS. IT IS THE CITY 5000 PATIENTS IN THE U.S. ABOUT 50% OF THEM ARE IN THE FRONT LINE. PEOPLE ACKNOWLEDGE THAT THIS WILL BE WIDELY USED IN THE FRONT LINE MYELIN, SETTING. IT OPENS UP A VERY LARGE A NEW MARKET FOR US. >> THANK YOU VERY MUCH FO <object width="320" height="260"><param name="movie" value="http://eplayer.clipsyndicate.com/cs_api/get_swf/"></param><param name="flashvars" value="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=466632&wpid=98"></param><param name="allowfullscreen" value="true"></param><embed src="http://eplayer.clipsyndicate.com/cs_api/get_swf/" flashvars="swfHome=eplayer.clipsyndicate.com&csEnv=p&cpt=8&va_id=466632&wpid=98" type="application/x-shockwave-flash" allowfullscreen="true" width="320" height="260"></embed></object> Healthcare, Finance News, Public Companies, Government, Technology News